5118dd1305c10fae75000001	female;Women;FEMALE;women;females;Females	0.9999991558915626
534df8c9aeec6fbd07000016	rheumatoid arthritis;Rheumatoid arthritis;RHEUMATOID ARTHRITIS	0.9999290880964069
534df8c9aeec6fbd07000016	RA	0.8786527432767726
531d7430267d7dd053000008	.ALPHA.-LIPOIC ACID;alpha-lipoic acid	0.3854601778468298
52bf1f2d03868f1b06000015	Completely;completely	0.13035031982908168
531d7430267d7dd053000008	CLONAZEPAM;clonazepam	0.7543466602984688
513ce3c8bee46bd34c000008	Adjacent;adjacent	0.5918847719548207
5173eb428ed59a060a000021	Associated;associated	0.0022951584121862446
534df8c9aeec6fbd07000016	multiple sclerosis;MULTIPLE SCLEROSIS	0.9784132331942447
51601071298dcd4e51000038	Porphyromonas gingivalis;PORPHYROMONAS GINGIVALIS	0.828314046212704
5324cf139b2d7acc7e00001f	the prevalence and medication use	0.04410093462621225
5319ac36b166e2b806000031	the tightly controlled spatial and temporal interaction of multiple factors	0.05223772893890205
51601071298dcd4e51000038	STREPTOCOCCUS PNEUMONIAE;Streptococcus pneumoniae	0.8249014613072633
531d7430267d7dd053000008	clinical;Clinical	0.09795848179496992
534df8c9aeec6fbd07000016	Alzheimer disease;ALZHEIMER DISEASE;Alzheimer's disease	0.9472750925779208
5149a61ed24251bc05000044	Omp2a porins	0.6101576005618755
51601071298dcd4e51000038	CHLAMYDIA PNEUMONIAE;Chlamydia pneumoniae	0.8801650993871887
5162e44f298dcd4e5100004a	ex vivo gene therapy	0.5106292468228011
5324cf139b2d7acc7e00001f	depression during childhood and adolescence	0.08614136949423194
51601071298dcd4e51000038	BACILLUS ANTHRACIS;Bacillus anthracis	0.8808311486802229
51601071298dcd4e51000038	group B streptococci;Group B Streptococcus	0.28640725987249077
51601071298dcd4e51000038	Theileria parva	0.8072834086191977
513ce3c8bee46bd34c000008	FGFR2;FGFR-2	0.6401444802154168
534df8c9aeec6fbd07000016	prion diseases;prion disease;PRION DISEASES;Prion Disease	0.46887675241475424
52ee9f55c8da898910000009	Different mutations	0.25332858483209847
5173eb428ed59a060a000021	an animal model	0.14966826241634723
5165932e298dcd4e51000059	libraries;Libraries	0.08480131051617762
51601071298dcd4e51000038	East Coast fever;East Coast Fever	0.07429524001174281
533ea8fcc45e133714000010	the selenocysteine insertion sequence (	0.27791225292057076
5149a61ed24251bc05000044	11 methods	0.11308506089372719
5156be75d24251bc05000088	Messenger RNA;RNA-mediated processing of messenger;mRNA	0.6779317283682592
52ee9f55c8da898910000009	a subtype of prolonged QT syndrome	0.07706078996598756
51601071298dcd4e51000038	swine dysentery vaccine development	0.4089710525821425
52b2d405f828ad283c000009	Types;types	0.00919484932470655
52b2d405f828ad283c000009	T Cells;T cells	0.48419114936461655
5165932e298dcd4e51000059	zebularine aglycon;(zebularine aglycon)	0.7607192350977435
5133b9455274a5fb0700000c	AAUAAA	0.8780394393483083
51601071298dcd4e51000038	Brachyspira hyodysenteriae	0.6344114034434232
51601071298dcd4e51000038	pigs	0.11019208287557689
513ce3c8bee46bd34c000008	several syndromic forms	0.15732138103321774
534df8c9aeec6fbd07000016	cancer;CANCER	0.20506923904825464
513ce3c8bee46bd34c000008	several syndromic forms of craniosynostosis	0.07957291697097207
513ce3c8bee46bd34c000008	Novel Mutation;novel heterozygous mutation	0.2859815223959098
533ec7abc45e133714000015	NELF;NELF)	0.999567151259414
52bf1f2d03868f1b06000015	the antinociceptive effect of L-DOPA	0.4216265694845458
5324cf139b2d7acc7e00001f	Premature ejaculation;Ejaculation, Premature	0.5704717319584109
513ce3c8bee46bd34c000008	girl;Girl	0.07415184556653474
51601071298dcd4e51000038	Echinococcus granulosus	0.6693653508272109
533ec7abc45e133714000015	DSIF;/DSIF;(DSIF)	0.9952285486987953
5319ac99b166e2b806000034	protein (GAP) activity toward Rheb	0.148897589210702
5319ac99b166e2b806000034	TBC1D7	0.8971765194777949
534df8c9aeec6fbd07000016	the protein citrullination	0.020209341277402558
514a11add24251bc05000054	luminal A and B	0.22250616302815598
513ce3c8bee46bd34c000008	FGFR2 (943G	0.6210116871357425
532dcfc9d6d3ac6a34000021	(HMT)(1) class enzymes	0.40349185422469347
52eeddfcc8da898910000010	ventricular arrhythmia;Ventricular arrhythmias;Arrhythmia, Ventricular;ventricular arrhythmias	0.8693722773499957
533ec7abc45e133714000015	the pause-	0.15022295779746597
52eeddfcc8da898910000010	PERIODIC PARALYSIS;familial periodic paralysis;periodic paralysis;Familial Periodic Paralysis	0.9950946422251085
534df8c9aeec6fbd07000016	the CNS	0.2420739675263992
51601071298dcd4e51000038	Helicobacter pylori;HELICOBACTER PYLORI	0.6681641481216425
513ce3c8bee46bd34c000008	FGFR3;FGFR3)	0.7247227699375302
5165932e298dcd4e51000059	2-(1H)-pyrimidinone	0.36771433136800163
51601071298dcd4e51000038	Mycobacterium tuberculosis;MYCOBACTERIUM TUBERCULOSIS	0.7563329816565255
534df8c9aeec6fbd07000016	peptide citrullination	0.39352420309723063
5173eb428ed59a060a000021	clinical;Clinical	0.08910129694615264
52eeddfcc8da898910000010	Mutations of KCNJ2	0.3015292115653016
51601071298dcd4e51000038	represents;Represent	0.08566359214992372
532dcfc9d6d3ac6a34000021	containing HMTase	0.25029888958821966
52eeddfcc8da898910000010	skeletal dysmorphisms	0.7275325525809335
5324cf139b2d7acc7e00001f	Fibromyalgia Syndrome;FIBROMYALGIA;fibromyalgia;fibromyalgia syndrome	0.8188916233163213
5319ac99b166e2b806000034	Decreased;decreased	0.0866928069704915
5149a61ed24251bc05000044	OMBBpred	0.6464415752229264
5156be75d24251bc05000088	These data	0.10070893492344618
52b2d405f828ad283c000009	synovial fibroblasts	0.8643247957113198
51601071298dcd4e51000038	Ehrlichia ruminantium	0.9314238312155206
5319ac99b166e2b806000034	TSC1 and TSC2	0.09852480405464177
5165932e298dcd4e51000059	the observed differences in cytotoxicity	0.05789933277072025
5319ac99b166e2b806000034	the association of TSC1 and TSC2	0.030072682448497486
5162e44f298dcd4e5100004a	Potential;potential	0.13004056556838262
52eeddfcc8da898910000010	abnormal QT-U complex	0.41656877892194816
532dcfc9d6d3ac6a34000021	N-terminal tails of histones	0.2129498745692916
5149a61ed24251bc05000044	protein-protein	0.07467354201661802
5319ac99b166e2b806000034	induction;Induction	0.5908272423996727
51601071298dcd4e51000038	Leishmania spp	0.7153939154226241
5321badd9b2d7acc7e00000a	Types;types	0.003543095927940032
5149a61ed24251bc05000044	oligomerization states	0.328254219196089
5165932e298dcd4e51000059	hydralazine;HYDRALAZINE	0.8065918740770494
5324cf139b2d7acc7e00001f	INSOMNIA;Insomnia;insomnia	0.6656271905888806
534df8c9aeec6fbd07000016	Study;study	0.11202014736389279
515c4f05298dcd4e51000006	PLB);PLB;phospholamban	0.9302533623502136
51601071298dcd4e51000038	Rhipicephalus microplus	0.8024555148686585
5324cf139b2d7acc7e00001f	bulimia;BULIMIA	0.6196279874374223
5324cf139b2d7acc7e00001f	benzodiazepine/alcohol dependence;Benzodiazepine dependence	0.4750802716196199
532f0b2cd6d3ac6a3400002c	Scoliosis;scoliosis;SCOLIOSIS	0.8040837337536696
532f0b2cd6d3ac6a3400002c	dural ectasia;Dural ectasia	0.9021925184823811
532f0b2cd6d3ac6a3400002c	PROTRUSIO ACETABULI;protrusio acetabuli	0.8065470460660846
532f0b2cd6d3ac6a3400002c	ligamentous laxity;Ligamentous laxity	0.7864600864817793
515c4f05298dcd4e51000006	SR(Ca)ATPase	0.7462943174170699
5324cf139b2d7acc7e00001f	-- Schizophrenia;schizophrenia	0.6515169585509786
532f0b2cd6d3ac6a3400002c	arachnodactyly;ARACHNODACTYLY;dolichostenomelia;DOLICHOSTENOMELIA	0.7453446201796107
5324cf139b2d7acc7e00001f	chronic pain disease;Chronic Disease	0.11808075460178057
5324cf139b2d7acc7e00001f	diabetic neuropathy;DIABETIC NEUROPATHY	0.75289306204161
532f0b2cd6d3ac6a3400002c	pectus excavatum and carinatum	0.49859881729346006
5324cf139b2d7acc7e00001f	serotonin receptor antagonists and reuptake inhibitors	0.544948112673848
51601071298dcd4e51000038	herpes simplex viruses	0.25935059758813556
5149aafcd24251bc05000045	protein-protein interaction;PPI);Protein-protein interactions;Protein interaction;PPI;PPIs;Protein-Protein Interactions;proteinâ€“protein interactions;protein-protein interactions;protein interaction;Protein-Protein Interaction	0.9999999999999996
5173eb428ed59a060a000021	Posterior fossa;posterior fossa	0.5676130899147245
513ce3c8bee46bd34c000008	A unique point mutation in the fibroblast growth factor	0.08734332984722176
514a11add24251bc05000054	Oncotype DX Recurrence Score	0.100543846125423
5162e44f298dcd4e5100004a	Convection-enhanced delivery	0.18636928889713797
532f0b2cd6d3ac6a3400002c	Otto pelvis	0.8503517634521918
515c4f05298dcd4e51000006	More;more	0.08497568609601522
5149aafcd24251bc05000045	Phosphorylation;eFIP;Extract;extracting;phosphorylation;Impact;impact;Functional;IMPACT;extract;Extracting	0.9945818823606719
51601071298dcd4e51000038	BRUCELLA MELITENSIS;Brucella melitensis	0.5646872548372598
5165932e298dcd4e51000059	procaine;PROCAINE	0.806769007256383
515c4f05298dcd4e51000006	potassium channel 2;POTASSIUM CHANNEL 2;KCNA4	0.8047522401462817
52b2d405f828ad283c000009	macrophages;macrophage;Macrophages;Macrophage	0.6493504912716481
51404dd723fec90375000002	absence	0.1788447646215871
5324cf139b2d7acc7e00001f	behavioral disorders in dementia	0.10751175284853651
5324cf139b2d7acc7e00001f	FLASHES, HOT;hot flashes	0.6470301889322956
5324cf139b2d7acc7e00001f	associated with;Associated with	0.0800491291848438
5173eb428ed59a060a000021	Alagille syndrome;ALGS;ALAGILLE SYNDROME;AGS;Alagille Syndrome	0.9998058518717575
5149aafcd24251bc05000045	PPInterFinder	0.7860984992278784
5173eb428ed59a060a000021	Spondylocostal dysostosis;Spondylocostal Dysostosis);Spondylocostal Dysostosis;SCDO1	0.7453324422726313
515c4f05298dcd4e51000006	KCNE1	0.8661127968421182
516545a8298dcd4e51000056	small integral membrane protein 1;SMIM1;SMALL INTEGRAL MEMBRANE PROTEIN 1	0.9452416702096239
515c4f05298dcd4e51000006	four;Four	0.08399723690449414
530cefaaad0bf1360c000012	atypical restless leg syndrome	0.041594868184000565
532f0b2cd6d3ac6a3400002c	genetics;Genetics	0.5860831753885115
532f0b2cd6d3ac6a3400002c	Consultation;consultation	0.5871766746427906
514168ab23fec9037500000a	STAT3	0.9285513984355984
516545a8298dcd4e51000056	cDNA Expression;Expression of SMIM1 cDNA	0.4033932907454958
51404dd723fec90375000002	S-adenosyl-L-methionine	0.7824357606593106
5149aafcd24251bc05000045	eFIP system	0.31653953665753215
514168ab23fec9037500000a	HIF-1 alpha;HIF-1alpha;HIF-1-Alpha;Hif1alpha;HIF-1Alpha;Hypoxia-Inducible Factor 1-Alpha;hypoxia-inducible factor (HIF)-1alpha;HIF1 alpha;HIF-1alpha protein;HIF)-1alpha	0.9838226679973564
514a11add24251bc05000054	the development	0.10856246325880975
5165932e298dcd4e51000059	ZCyt	0.8851109451947851
52ef7754c8da898910000014	H-NS	0.4544990157451869
532f55fed6d3ac6a34000036	beta-glucocerebrosidase;Acid Beta-Glucosidase;glucocerebrosidase (;acid beta-glucosidase;glucocerebrosidase;Glucocerebrosidase;Beta-Glucocerebrosidase	0.9983818576388821
515c4f05298dcd4e51000006	myocyte;Myocytes;myocytes;Myocyte	0.5964127647652375
51404dd723fec90375000002	Link;linked	0.08385862026901061
52d1389303868f1b06000032	Electroporation;electroporation	0.7514754800643231
515c4f05298dcd4e51000006	HCN2	0.8477309527139324
5321badd9b2d7acc7e00000a	CD34	0.6568392268990357
515c4f05298dcd4e51000006	HCN4	0.848835825632774
514168ab23fec9037500000a	NF-ÎºB	0.9085249693035413
5165932e298dcd4e51000059	Closed;closed	0.08454887744604116
52d1389303868f1b06000032	Electric field;electric field	0.06880663650522541
51404dd723fec90375000002	slow;Slow	0.07924928908163224
516be1d6298dcd4e5100006a	Autosomal dominant;autosomal dominant	0.3591510219315266
5324cf139b2d7acc7e00001f	postprostatectomy established stress urinary incontinence	0.26517927649996215
515c4f05298dcd4e51000006	KCND2	0.8739367221364391
515c4f05298dcd4e51000006	KCND3	0.9097008549574693
530cefaaad0bf1360c000012	Iron;IRON;iron	0.8750013237340873
52bf1f4503868f1b06000016	schizophrenic disorder;Schizophrenic Disorder;-- Schizophrenia;schizophrenia	0.8934558732526464
516545a8298dcd4e51000056	Haemolytic disease	0.25458113157909323
5173eb428ed59a060a000021	6qter deletions	0.6484297368108154
5149aafcd24251bc05000045	indications of protein-protein interactions	0.010005064156290577
532f55fed6d3ac6a34000036	Gaucher disease (GD;Gaucher disease (GD)	0.44357006918979947
51404dd723fec90375000002	south;South	0.08208227117642969
516be1d6298dcd4e5100006a	recessive inheritance	0.4797211543660756
52bf1f4503868f1b06000016	children and adolescents with a schizophrenic disorder	0.05110696936605609
515c4f05298dcd4e51000006	KCND2/3 transcription	0.8188651815145302
52d1389303868f1b06000032	lipids;Lipids;lipid;Lipid	0.8362439765854445
51404dd723fec90375000002	AdoHcy;AdoHCy	0.8373617261420097
5165932e298dcd4e51000059	5-fluorodeoxycytidine;5 fluorodeoxycytidine	0.4765999026485025
52bf1f4503868f1b06000016	SCHIZOAFFECTIVE DISORDER;schizoaffective disorder	0.27584045389183925
52bf1f4503868f1b06000016	delusional disorder;Delusional Disorder	0.3656201273213008
514a11add24251bc05000054	December	0.6693388094830159
5353aedb288f4dae47000006	X inactivation specific transcript;XIST) gene;Xist;XIST Gene;XIST;X-inactivation specific transcript (;X INACTIVATION-SPECIFIC TRANSCRIPT;X inactivation-specific transcript;Xist) gene;X-inactivation specific transcript;Xist gene	0.9999986440633577
5165932e298dcd4e51000059	FdC	0.6110100584996173
516c0ebc298dcd4e5100006e	Which genes	0.006898678216175796
517295c18ed59a060a000016	microRNAs;miRNAs;MicroRNAs;miRNA	0.94289454232417
51542dc3d24251bc0500007e	the symptoms of abacavir hypersensitivity	0.0064090319081056245
5149aafcd24251bc05000045	GeneView	0.7973135983312203
516c0ebc298dcd4e5100006e	Iodine-;iodine	0.6569537435328747
51542dc3d24251bc0500007e	Rash;RASH;skin rash;rash;Skin Rash	0.8789009770020557
52bf1f4503868f1b06000016	risperidone;RISPERIDONE	0.6606885615316936
514168ab23fec9037500000a	the shift	0.03617084785686293
51542dc3d24251bc0500007e	fever;FEVER	0.13574778258567713
51542dc3d24251bc0500007e	occasionally;Occasionally	0.10109216941013462
52ef7754c8da898910000014	HU	0.9982853329818147
5321badd9b2d7acc7e00000a	vaccination with combination	0.22200435800514803
52bf19c503868f1b06000001	Autosomal dominant;autosomal dominant (AD) inheritance;autosomal-dominant;autosomal dominant inheritance;Autosomal Dominant Inheritance;autosomal-dominant inheritance;autosomal dominant	0.9994862306967505
5324cf139b2d7acc7e00001f	Erectile Dysfunction;erectile dysfunction	0.7569961366744495
5324cf139b2d7acc7e00001f	ymptomatic therapy	0.3422093702606921
52ef7754c8da898910000014	the pool of vegetative phage DNA	0.1638352669198934
516c0ebc298dcd4e5100006e	ChREBP;CHREBP	0.843577276340889
5165932e298dcd4e51000059	5;>5	0.5798282500037811
5353aedb288f4dae47000006	inactive-specific transcript	0.5944032798745126
5149aafcd24251bc05000045	iHop;IHOP	0.6521369552433349
5353aedb288f4dae47000006	X inactive-specific transcript (XIST) gene;X-inactive-specific transcript (Xist) gene	0.5882558957223604
5165932e298dcd4e51000059	5,6-dihydro-5-azacytosine	0.48465535561616496
51542dc3d24251bc0500007e	anaphylactic shock;ANAPHYLACTIC SHOCK	0.40762318988563623
5324cf139b2d7acc7e00001f	PE	0.8005408728989357
5353aedb288f4dae47000006	humans	0.10455085742294512
517295c18ed59a060a000016	piRNA;piRNAs	0.7562871163373943
530cefaaad0bf1360c000012	Insufficient;insufficient	0.6778775398372604
517295c18ed59a060a000016	snoRNAs;snoRNA	0.8665082103896466
5165932e298dcd4e51000059	DZCyt	0.7885342651568484
517295c18ed59a060a000016	scaRNAs	0.6713657058433377
52bf19c503868f1b06000001	weakness;WEAKNESS	0.19260542600283614
515c4f05298dcd4e51000006	alpha-myosin heavy chain;Alpha heavy chain	0.5699718830411534
515c4f05298dcd4e51000006	sarcoplasmic reticulum calcium adenosine triphosphatase;sarcoplasmic reticulum calcium-activated adenosinetriphosphatase	0.6788957050125939
52ef7754c8da898910000014	IHF	0.7403643057760989
514168ab23fec9037500000a	SIRT6	0.8544211026161922
5321badd9b2d7acc7e00000a	better;Better	0.0833965654371976
5324cf139b2d7acc7e00001f	SUI	0.6541310156190538
51542dc3d24251bc0500007e	gastrointestinal disorders;GASTROINTESTINAL DISORDERS	0.2910190267103902
52bf19c503868f1b06000001	made;Make	0.0841521259389211
51542dc3d24251bc0500007e	Respiratory symptoms NOS;Respiratory symptoms	0.1218473748181499
52d1389303868f1b06000032	correlations between the molecular structures	0.05637837412805052
5324cf139b2d7acc7e00001f	Preliminary results on the off-label use	0.008379794367027137
514168ab23fec9037500000a	increased activity;increased Hif1alpha activity	0.27283039524440805
517295c18ed59a060a000016	Distance	0.10865540590600971
514168ab23fec9037500000a	c-Myc;c myc	0.9742072999868251
517295c18ed59a060a000016	snRNAs;snRNA	0.7883967998465075
51477de5d24251bc05000020	GLAND, PITUITARY;Pituitary Glands;pituitary glands;pituitary gland	0.8340781312573545
516c0ebc298dcd4e5100006e	HR	0.6537650012298573
52ef7754c8da898910000014	homology does	0.39726128082005907
5324cf139b2d7acc7e00001f	reliable evidence of safety and efficacy	0.05283939423153577
51542dc3d24251bc0500007e	VOMITING;vomiting	0.5887382730731332
51542dc3d24251bc0500007e	DIARRHEA;diarrhoea	0.5886659595302471
514168ab23fec9037500000a	Coordinated;coordinated	0.08714251033494495
5321badd9b2d7acc7e00000a	100% penetrance	0.6222307678134176
5173eb428ed59a060a000021	JAG1 gene mutations	0.1670094124495753
52d1389303868f1b06000032	several clinical trials	0.0954704408868203
5165932e298dcd4e51000059	4'-thio-2'-deoxycytidine	0.8334593758374225
514168ab23fec9037500000a	Oct1	0.6605192623504399
5353aedb288f4dae47000006	non-coding RNAs (ncRNAs);non-coding RNAs (ncRNAs	0.7333393389635304
51542dc3d24251bc0500007e	cough;COUGH	0.6074130936845106
532f55fed6d3ac6a34000036	Entire;entire	0.08436624819145164
514168ab23fec9037500000a	pVHL;PVHL	0.7492073717928484
5321badd9b2d7acc7e00000a	MELANOMA;melanoma	0.7887318020796774
515c4f05298dcd4e51000006	DRON	0.6599455289747973
5149aafcd24251bc05000045	PPI pairs	0.1768953069402662
52ef7754c8da898910000014	specific recombination	0.23340482500550505
52d1389303868f1b06000032	Cytotoxicity;cytotoxicity	0.5975329549787386
51477de5d24251bc05000020	pancreas;Pancreatic;PANCREAS;pancreatic	0.7946058545967751
52bf202003868f1b06000018	refractory epilepsy	0.7323752227070687
517539af8ed59a060a000026	COX-2	0.8498565164875378
5353aedb288f4dae47000006	the regulatory RNA	0.07738638849140551
5165932e298dcd4e51000059	Treatment of Schizosaccharomyces pombe	0.17930249712530272
532ff917d6d3ac6a34000038	H3K36Me3;H3K36me3	0.8137214992897025
52d1389303868f1b06000032	liposomes;Liposomes	0.7162302610815936
517539af8ed59a060a000026	in;In;Found;found;Present;present	0.0377043883955612
52bf202003868f1b06000018	First;first	0.1164138860608871
52d1389303868f1b06000032	Anti-Antibodies;anti-transferrin receptor antibodies	0.7956511325970401
517539af8ed59a060a000026	estrogen receptor (ER)alpha gene;estrogen receptor alpha gene	0.6915335614737544
5149aafcd24251bc05000045	PPI finder;PPI Finder (;PPI Finder	0.8560491338323531
51477de5d24251bc05000020	tumor development	0.06351066362454642
517539af8ed59a060a000026	a pronounced increase	0.1490666578753159
5324cf139b2d7acc7e00001f	a remarkable rise in the off-label use	0.007685891360704108
517539af8ed59a060a000026	casq2;CASQ2 gene;CASQ2;casq2 gene	0.4090073187805612
5324cf139b2d7acc7e00001f	the mid-1980s	0.12735704972721743
51542e44d24251bc05000081	epidermal growth factor receptor gene;EGFR) gene;epidermal growth factor receptor (EGFR) gene;EGFR gene	0.8121956899538492
52bf202003868f1b06000018	epilepsy;EPILEPSY	0.9540486486363683
52ef7754c8da898910000014	like protein HU	0.41787253019431264
52bf1f1303868f1b06000014	antioxidant;Antioxidant	0.9516114870278922
51542e44d24251bc05000081	the most common histologic subtype	0.17023626655353297
530cefaaad0bf1360c000012	cystic fibrosis;CYSTIC FIBROSIS	0.8502646319903399
5166f41a298dcd4e5100005b	antimalarial activity	0.40135938159359075
514168ab23fec9037500000a	metabolic switch	0.2617834925537138
52bf1f1303868f1b06000014	found;in;In;Found	0.0587319475183292
5173eb428ed59a060a000021	had deletions	0.251018255412817
532ff917d6d3ac6a34000038	part of alternative splicing regulation	0.05837233334285049
5149aafcd24251bc05000045	Paired-PPI Finder;Paired-PPI Finder (	0.6339433989547552
5353aedb288f4dae47000006	begins;Begin	0.06935510089358435
5166f41a298dcd4e5100005b	BIX-01294;BIX 01294	0.9826526935917145
52d2818403868f1b06000033	TALEN	0.7417109567486089
51477de5d24251bc05000020	one;ONE	0.11689945671768462
515c4f05298dcd4e51000006	TRalpha1 to alpha	0.3512736435832369
516c0ed3298dcd4e5100006f	phosphoenolpyruvate-carboxykinase;phosphoenolpyruvate carboxykinase	0.7086144802943061
52bf1f1303868f1b06000014	regulation;Regulation	0.08979476964374013
517539af8ed59a060a000026	cTnT	0.8088954504230477
516c0ed3298dcd4e5100006f	pyruvate kinase;Pyruvate Kinase	0.7262608829047328
52d2818403868f1b06000033	this opportunity	0.10230391483985145
532ff917d6d3ac6a34000038	lysine;LYSINE	0.7843007273329116
5324d0169b2d7acc7e000022	MINOXIDIL;minoxidil	0.7302158432649656
5324d0169b2d7acc7e000022	Finasteride;FINASTERIDE;finasteride;finasteride)	0.9295143951757048
5173eb428ed59a060a000021	transmembrane	0.6228545283571639
5166f41a298dcd4e5100005b	TM2-115	0.7601335015783685
514168ab23fec9037500000a	Src;SRC;(Src)	0.7365987845185138
514168ab23fec9037500000a	results;Result	0.08529345838110539
52bf202003868f1b06000018	refractory, partial seizures;Refractory seizures;refractory partial-onset seizures	0.8442945652809795
515c4f1f298dcd4e51000007	tr beta 1;TRbeta1;TR beta 1	0.9354988867477809
5149aafcd24251bc05000045	Very high;very high	0.07843324965714774
51477de5d24251bc05000020	hormone excess syndromes	0.22552693162067738
515c4f1f298dcd4e51000007	HCN4	0.8198104638237753
514168ab23fec9037500000a	Then;then	0.08279041509185132
5166f41a298dcd4e5100005b	P. falciparum 3D7 parasites in culture	0.3238237476867958
516c0ed3298dcd4e5100006f	D1	0.8997216752523498
5166f41a298dcd4e5100005b	inhibit malaria parasite	0.5959694706743608
51740da48ed59a060a000024	the bioinformatics tools for gene structure prediction	0.0025005653007105486
52ef7754c8da898910000014	NS	0.6976765179866153
52bf202003868f1b06000018	A discussion	0.10137055258951418
52d2818403868f1b06000033	estrogen receptor Î±	0.6864336800460715
530cefaaad0bf1360c000012	The syndrome	0.013905908502980204
515c4f1f298dcd4e51000007	contractile function	0.33623405748030905
515c4f1f298dcd4e51000007	SERCA	0.7140755460083642
5149aafcd24251bc05000045	PIE	0.9325129819707393
514168ab23fec9037500000a	HNF4alpha	0.6672342292007117
5149aafcd24251bc05000045	Protein interaction information extraction system	0.021556925309154804
5322d3cb9b2d7acc7e000010	MEC-17	0.9673450021478961
517539af8ed59a060a000026	sarco(endo)plasmic reticulum Ca2+-ATPases;sarco(endo)plasmic reticulum Ca2+-ATPase	0.4102562075841805
5353aedb288f4dae47000006	sequence;Sequence	0.08204039894429675
52bf202003868f1b06000018	Analgesic;analgesic	0.6823184906573267
52bf202003868f1b06000018	CNS disorders NOS;CNS disorders	0.42595090357994203
51740da48ed59a060a000024	This problem	0.1026601074595908
516e5f25298dcd4e5100007d	exhibited;Exhibit	0.0891921141185591
52ef7754c8da898910000014	the major DNA-binding proteins	0.13624866292829374
517539af8ed59a060a000026	SERCAs;(SERCAs)	0.6704735641712506
51477de5d24251bc05000020	system;System	0.08315905955336651
517539af8ed59a060a000026	human SERCA2 gene	0.19943666620429906
514217a6d24251bc05000005	GeneView	0.7171061443226358
53318685d6d3ac6a3400003d	Autosomal dominant;autosomal dominant	0.6055362875714074
530cf4d5e2bfff940c000003	indazoles;Indazoles	0.8099018519409643
52ef7754c8da898910000014	concentrations;Concentrations	0.08672631215714184
52d2818403868f1b06000033	HBB mutations	0.7209229856053427
51477de5d24251bc05000020	nodular hyperplasia	0.8662918357533359
530cf4d5e2bfff940c000003	2;+2	0.7098955910618681
517539af8ed59a060a000026	SRF	0.7978208883023086
51740da48ed59a060a000024	by;BY	0.10563303853743894
51740da48ed59a060a000024	SCGPred;SCG-Pred	0.8315444515882694
516e5f25298dcd4e5100007d	DOXORUBICIN;doxorubicin;doxorubicin (	0.9876187991484138
5322d3cb9b2d7acc7e000010	Extending;extent;Extent;extending	0.0990803305647677
51740da48ed59a060a000024	multiple sources of evidence	0.1608673546225316
516e5f25298dcd4e5100007d	Recent reports	0.08924664077578484
5325fdf0600967d132000001	artificial urinary sphincter;artificial urethral sphincter;Artificial sphincter;Artificial urinary sphincter	0.391624849435825
53318685d6d3ac6a3400003d	to;TO	0.08444198124842395
516e5f25298dcd4e5100007d	vector;Vector	0.6248388391212177
5149aafcd24251bc05000045	PPI information	0.33665393872022953
514217a6d24251bc05000005	PPI finder;PPI Finder	0.842222744764958
515d1ff7298dcd4e51000009	pluripotent;Pluripotent;pluripotency	0.9281857116740986
52bf202003868f1b06000018	antiepileptic effectiveness in different rodent seizure models	0.17359905426101246
5325fdf0600967d132000001	artificial urinary sphincter (AUS) implantation	0.5495583689025368
53355befd6d3ac6a34000046	Support, NOS;support	0.0859234626428243
5354f289288f4dae47000008	MITIE	0.599351066602472
53355befd6d3ac6a34000046	CSBB-ConeExclusion	0.7438053990826775
52bf202003868f1b06000018	Recent results	0.11921349518003317
5322d3cb9b2d7acc7e000010	endothelial cells;Endothelial Cells	0.3746688960972483
52bf1f1303868f1b06000014	5 Gy irradiation	0.750710616237048
5166f41a298dcd4e5100005b	cell inhibition	0.24598983099112764
5354f289288f4dae47000008	Montebello	0.6586693369690545
53355befd6d3ac6a34000046	HADDOCK;Haddock	0.909368544033792
52bf202003868f1b06000018	Against;against	0.08430571385516487
5166f41a298dcd4e5100005b	trichostatin A;TRICHOSTATIN A	0.32945294822535826
5166f41a298dcd4e5100005b	3-deazaneplanocin A	0.8268328099391781
5166f41a298dcd4e5100005b	DZNep	0.85955184819504
5149aafcd24251bc05000045	the PPI sentences	0.0517282267660597
51740da48ed59a060a000024	MetWAMer	0.6664007186052072
5149aafcd24251bc05000045	a set of words	0.0560460474041873
51740da48ed59a060a000024	GeneSeqer	0.8152508348671225
5354f289288f4dae47000008	Cufflinks	0.8833351820739432
5166f41a298dcd4e5100005b	TSA	0.6528390346232967
5325fdf0600967d132000001	AUS	0.7660020861355209
5149aafcd24251bc05000045	allows;allow	0.10444806092863226
5325fdf0600967d132000001	ISD	0.6695921113843566
52d2818403868f1b06000033	CRISPR/Cas	0.7390127857358484
515d1ff7298dcd4e51000009	G1/S transition;G1 to S transition;G1/S Transition	0.8223353234222328
517539af8ed59a060a000026	SERCA	0.6441157844257008
51740da48ed59a060a000024	WebScipio	0.6932480618827631
515d1ff7298dcd4e51000009	stem cell transcription factor;Stem Cell Factor	0.21475358907714664
530cf4d5e2bfff940c000003	this paper	0.10056631661328086
517539af8ed59a060a000026	T3R beta	0.6581262775604539
530cf4d5e2bfff940c000003	quinoline-3-carbonitriles	0.684019340347185
5149aafcd24251bc05000045	extraction method	0.2597962876075698
5354f289288f4dae47000008	Traph	0.6511509720684199
52f112bb2059c6d71c000002	RNA Pol II;RNA Polymerase II;RNA pol II;RNA polymerase II	0.8929725138036995
515d1ff7298dcd4e51000009	glioma stem cells	0.25488560963323875
52d8494698d0239505000007	genes;Genes	0.009134456261527256
515d1ff7298dcd4e51000009	gliomasphere clonogenicity	0.6503861156623176
52bf202003868f1b06000018	chemoconvulsants pentylenetetrazol	0.6347088762135642
517539af8ed59a060a000026	transcription factor	0.24043680395840336
532c12f2d6d3ac6a3400001d	negative chronotropy;Negative Chronotropy	0.2908939728802278
52d8494698d0239505000007	GFI1B	0.6915711208381139
515d1ff7298dcd4e51000009	S-phase transition and proliferation in the developing embryo	0.11282097287185638
52d8494698d0239505000007	neurobeachin-like 2	0.6746883581307974
53355befd6d3ac6a34000046	. GalaxyDock	0.5349698512436872
5149aafcd24251bc05000045	OntoGene	0.6713373307069674
52d8494698d0239505000007	NBEAL2 gene;NBEAL2;NBEAL2 as the causative gene	0.9990745005245322
515d1ff7298dcd4e51000009	our results	0.11109984006593968
5354f289288f4dae47000008	a framework for efficient and comprehensive representation	0.05587281165102619
514217a6d24251bc05000005	PreBIND	0.8247510960771014
5166f41a298dcd4e5100005b	ACT;adoptive immunotherapy;acting	0.5523354218673244
5354f289288f4dae47000008	a pipeline	0.24713350105700546
5149aafcd24251bc05000045	LAITOR	0.7904075191493856
51477de5d24251bc05000020	renal angiomyolipoma;Renal Angiomyolipoma	0.8164973533891119
5354f289288f4dae47000008	DRUT	0.6692975094198892
53355befd6d3ac6a34000046	DOCK;Dock;docked	0.44675605561952986
51740da48ed59a060a000024	SplicePredictor	0.7299745235888669
530cf4d5e2bfff940c000004	use;uses	0.162508382891408
52d832dd98d0239505000003	K/R-X-K/R-X-X-S/T	0.22692355785007798
517539af8ed59a060a000026	consensus;Consensus	0.0812862202131784
53355befd6d3ac6a34000046	PHASE;Phase	0.08105674791186819
5322d3cb9b2d7acc7e000010	2;+2	0.6085183195889687
516e5f25298dcd4e5100007d	etoposide (VP-16)	0.6700830887229094
52ed795098d0239505000032	repressor;transcriptional repressor;Transcriptional Repressor;transcription repressor;transcription factor BACH1 serving as a repressor;repressor of HO-1 transcription;Repressor;Transcription Repressor	1.0
5149aafcd24251bc05000045	string;STRING	0.18639359077401543
5322d3cb9b2d7acc7e000010	NAD)--dependent tubulin deacetylase	0.34291516979245545
5354f289288f4dae47000008	MISO;Miso	0.6390495894139528
52f112bb2059c6d71c000002	Myc	0.6521403033434002
52d832dd98d0239505000003	serine/threonine	0.6834973477236435
516e5f25298dcd4e5100007d	mitoxantrone;MITOXANTRONE	0.9018496360565277
517539af8ed59a060a000026	phosphoglycerate mutase;Phosphoglycerate Mutase;PGAM-M	0.8696242256332272
52e0c9a298d0239505000010	H4K20me3	0.6863008831834969
52e0c9a298d0239505000010	H3K9me3	0.694519728561752
52e0c9a298d0239505000010	H3K79me3	0.6968839258862535
52d832dd98d0239505000003	pSer-Xaa-Xaa-Ser	0.5538684149640931
52f112bb2059c6d71c000002	-product of methylation reactions	0.07987563906994717
515d1ff7298dcd4e51000009	cell fate determination	0.1541859067272684
51477de5d24251bc05000020	appear;APPEAR	0.09732287948630197
51740da48ed59a060a000024	DGSplicer	0.6534791697465593
5354f289288f4dae47000008	coverage	0.10508230603262973
5149aafcd24251bc05000045	social, part-of and locational relations between entities	0.12250965418000262
5354f289288f4dae47000008	POME	0.6658545900865351
52d832dd98d0239505000003	SLS and acidic cluster motifs	0.08206085527919589
52f77f042059c6d71c000029	renal angiomyolipoma;renal angiomyolipomas;Renal Angiomyolipoma	0.6078000869780255
52d832dd98d0239505000003	two;Two	0.08635421668600968
53355befd6d3ac6a34000046	DockRank	0.8098311761300145
52f77f042059c6d71c000029	surveillance	0.10966651582968569
515da6e2298dcd4e51000010	Oxcarbazepine;OXCARBAZEPINE	0.725648501609151
52f112bb2059c6d71c000002	Covalent;covalent	0.5803124981014685
53355befd6d3ac6a34000046	query protein	0.10361152293822187
530cf4d5e2bfff940c000004	Correlative;correlative	0.5669296609048661
5354f289288f4dae47000008	RSEM	0.6630777002801875
52f77f042059c6d71c000029	subependymal giant cell astrocytoma (SEGA);subependymal giant cell astrocytoma (SEGA	0.4988745549648179
518cca6f310faafe0800000a	change;Change	0.09920196588826997
53262cdcd6d3ac6a34000003	Epidural blood patching;epidural blood patch;Blood Patch, Epidural;Epidural blood patch	0.999905485740684
51740da48ed59a060a000024	TAP	0.11769009577464012
518cca6f310faafe0800000a	miR-1	0.7166690515794916
518cca6f310faafe0800000a	miR-133	0.6873969913929279
518cca6f310faafe0800000a	miR-208a	0.6839504089521862
52e0c9a298d0239505000010	only;Only	0.11935770045868259
518cca6f310faafe0800000a	miR-206	0.7076829781998386
52d832dd98d0239505000003	SerP/ThrP-Xaa-Xaa-Ser/Thr	0.623947456880165
51740da48ed59a060a000024	GeneBuilder	0.7831237039273423
51740da48ed59a060a000024	silico prediction	0.056060127939448166
518cca6f310faafe0800000a	the development	0.11310617096395138
51477de5d24251bc05000020	malignant, tumors;malignant tumors	0.3936536130830265
52f77f042059c6d71c000029	SEIZURES;seizures	0.6565672417316125
5354f289288f4dae47000008	IsoformEx	0.6526792858217113
514217a6d24251bc05000005	techniques	0.21106567414079858
52f77f042059c6d71c000029	autistic behaviour);autistic behaviour;Autistic behavior	0.619895212118942
516e5f25298dcd4e5100007d	ACLARUBICIN;aclarubicin	0.8196133281156247
515da6e2298dcd4e51000010	Ketamine;ketamine;KETAMINE	0.8277295090749982
52eea4dcc8da89891000000c	Autosomal Recessive Inheritance;autosomal-recessive;Autosomal recessive;autosomal recessive inheritance;autosomal-recessive inheritance;autosomal recessive	0.9831269609812033
5149199dd24251bc05000040	PYRIDOSTIGMINE;Pyridostigmine;pyridostigmine	0.9714119120067781
52f112bb2059c6d71c000002	the 5' terminal guanosine residue of the cap structure	0.08375562660403005
53355befd6d3ac6a34000046	HotLig	0.7103923090086623
5149aafcd24251bc05000045	Hidden Vector State model	0.10750452012958532
518cca6f310faafe0800000a	miR-494	0.6584295131136368
52f112bb2059c6d71c000002	G;g%	0.569388391961845
52fc8b772059c6d71c00006e	honokiol;Honokiol	0.7803432471683563
52f77f042059c6d71c000029	Pulmonary lymphangioleiomyomatosis	0.8049517273005329
53355befd6d3ac6a34000046	the Connolly surface of a protein	0.05046199745408106
516e5f25298dcd4e5100007d	DNR;DAUNORUBICIN;daunorubicin	0.6496609052184552
5354f289288f4dae47000008	NEUMA	0.6521403033434002
53355befd6d3ac6a34000046	ZDOCK	0.8064194810840226
515da6e2298dcd4e51000010	Phantom Pain;phantom pain	0.08169147338312406
52e0c9a298d0239505000010	H3K27me2	0.8911200701524623
516c3960298dcd4e51000073	DNMT1;DNMT-1;Dnmt1	0.9832054190441338
518cca6f310faafe0800000a	MIR-21;miR-21	0.8275575119853857
52e0c9a298d0239505000010	H3K9me2	0.7004743422805484
52f129d92059c6d71c000009	myotonic dystrophy type 2;MYOTONIC DYSTROPHY 2	0.41550191379829954
52e0c9a298d0239505000010	H3K27me1	0.6993649472766065
5149aafcd24251bc05000045	regenerating	0.7366839060908766
5149aafcd24251bc05000045	cells;Cells	0.13519955268461173
515da6e2298dcd4e51000010	PREGABALIN;Pregabalin	0.7887123935063137
518cca6f310faafe0800000a	miR-146a	0.6818824387513409
518cca6f310faafe0800000a	miR-222);miR-222	0.6888784687468388
530cf4d5e2bfff940c000004	Network-based methods	0.12087408200035406
51434c74d24251bc0500000c	beta-barrel transmembrane proteins	0.05997679364712947
518cca6f310faafe0800000a	miR-20a	0.6769751468047003
516c3960298dcd4e51000073	this traditional model	0.09682539666242931
515da6e2298dcd4e51000010	epilepsy;EPILEPSY	0.7082790884164247
518cca6f310faafe0800000a	miR-221)	0.6728121235650466
51740da48ed59a060a000024	HSPL;hSPL	0.7890954609569912
53355befd6d3ac6a34000046	SOL	0.8576514350134299
53355befd6d3ac6a34000046	DISCORE	0.5623845217572548
51740da48ed59a060a000024	Hexon;(HEXON);HEXON	0.6862125473353401
516c3960298dcd4e51000073	DNMT2;DNMT2);Dnmt2	0.9768267760671887
52f129d92059c6d71c000009	ATAXIA, FRIEDREICH;Friedreich ataxia	0.7401133591743937
52f129d92059c6d71c000009	SPINOCEREBELLAR ATAXIA 10;spinocerebellar ataxia type 10	0.4590976458003107
52fc8b772059c6d71c00006e	activator protein-1;ACTIVATOR PROTEIN 1	0.5718596315566516
52f77f4d2059c6d71c00002a	RNA GUANINE-7-METHYLTRANSFERASE;RNMT;RNA guanine-7 methyltransferase	0.930330589140232
5358e067f1005d6b5800000b	CRP family member	0.14541060658341562
52f129d92059c6d71c000009	OPTIC ATROPHY 1;autosomal dominant optic atrophy;optic atrophy 1;Autosomal dominant optic atrophy;Autosomal Dominant Optic Atrophy	0.8951564064023901
52f77f4d2059c6d71c00002a	RNA guanylyltransferase and 5' phosphatase;RNA guanylyltransferase and 5'-phosphatase	0.7377280407649018
516c3960298dcd4e51000073	DNMT3;Dnmt3	0.7922481059371229
518cca6f310faafe0800000a	Health;healthy	0.08708243033953254
5149af96d24251bc05000046	Identification	0.11026295069665262
51740da48ed59a060a000024	RNASPL);RNASPL	0.6621919410743642
51434c74d24251bc0500000c	TMBETAPRED-RBF	0.542317176589665
5149af96d24251bc05000046	MosaicFinder	0.7101760728896328
516e7fda298dcd4e51000081	S-adenosylmethionine;AdoMet;S adenosylmethionine;(AdoMet);SAM	0.9797745555577934
51740da48ed59a060a000024	HBR);HBR	0.6742757289959737
51434c74d24251bc0500000c	TMBETADISC-RBF	0.5768343166610467
518cca6f310faafe0800000a	miR-133a	0.652790603531528
5149af96d24251bc05000046	fused gene families in sequence similarity networks	0.07477108118908235
518cca6f310faafe0800000a	miR-133b	0.653244592235967
52f77f4d2059c6d71c00002a	and;And	0.08606346513748557
5149af96d24251bc05000046	Program;program	0.1343852570736706
51434c74d24251bc0500000c	TMB finding pipeline	0.2880957599824365
5157539ed24251bc0500008a	CRISPR-Cas	0.6138069815352366
53355befd6d3ac6a34000046	template;TEMPLATE	0.7799748685511595
515da6e2298dcd4e51000010	the majority of those	0.03697170651880494
518cca6f310faafe0800000a	healthy young males (n	0.23724250456540866
52fc8b772059c6d71c00006e	Quinoline;quinoline	0.7782509826390003
52eea509c8da89891000000d	KCNQ1 gene;KCNA9;genes KCNQ1;KVLQT1;Kv7.1;KVLQT1);KCNQ1;KCNQ1 Gene	0.9999413521673255
52f129d92059c6d71c000009	pathogenic;Pathogenic	0.5833475598239307
52fe54252059c6d71c000079	H-NS	0.4642364209233341
51434c74d24251bc0500000c	Several;several	0.19430539356641435
52fe54252059c6d71c000079	HU	0.847699780380425
5358e067f1005d6b5800000b	F-ascin;fascin;Fascin	0.9981674001436612
51434c74d24251bc0500000c	PV	0.7036886243301774
52f129d92059c6d71c000009	MENKES DISEASE;Menkes disease	0.47183721237102594
52fe54252059c6d71c000079	IHF	0.6657629185743881
515da6e2298dcd4e51000010	lidocaine 5% patches for chronic localized neuropathic pain	0.05180869713459348
515da6e2298dcd4e51000010	chronic localized neuropathic pain from a variety	0.02910337746106872
52e0c9a298d0239505000010	unexpressed euchromatin	0.9028430326655432
53355befd6d3ac6a34000046	AutodockVina;AutoDock Vina	0.7905930111756074
5149199dd24251bc05000040	NEOSTIGMINE;neostigmine	0.9097596922782442
52eea509c8da89891000000d	a three-generation family with a severe phenotype	0.05627263964929425
52eea509c8da89891000000d	nine;Nine	0.1270434927107304
516e7fda298dcd4e51000081	Adenosylmethionine;adenosylmethionine	0.8096432434318004
51434c74d24251bc0500000c	Relative;relative	0.08411677894015608
530cf4d5e2bfff940c000004	gene prioritization method	0.00987222286199187
52fc8b772059c6d71c00006e	nhibitors of tumor progression loci-2 (Tpl2) kinase and tumor necrosis factor alpha (TNF-alpha) production	0.06199043782861515
5157539ed24251bc0500008a	a RNAi-like defense mechanism against bacteriophages	0.04252761380571497
515da6e2298dcd4e51000010	opioid therapy	0.4403088578237111
5358e067f1005d6b5800000b	F-actin bundling	0.7255984090235205
5177def18ed59a060a000034	a third of IPMN adenomas	0.17709464897369007
52e0c9a298d0239505000010	Mammalian Cell;mammalian cells	0.36988432305364544
5177def18ed59a060a000034	Point Mutations;point mutations	0.5703376361822102
52eea509c8da89891000000d	HERG);KCNH2;human ether-a-go-go-related gene;HUMAN ETHER-A-GO-GO-RELATED GENE;HERG	0.9989554667750136
53355befd6d3ac6a34000046	DockTrina	0.589009757479807
5149af96d24251bc05000046	database;Database	0.27811903440238905
51bdd9c2047fa84d1d000002	LAMP-2A;LAMP2A;lamp2a;Lamp2a;Lamp-2a;Lamp2A	0.9912613876138433
5157539ed24251bc0500008a	the CRISPR associated system (CASS	0.1574331707723039
516e7fda298dcd4e51000081	(SMM);methylmethionine;methyl methionine;methyl donor for Met;Methylmethionine;SMM;(SMM	0.9449103710104415
5149199dd24251bc05000040	symptomatic treatment	0.41934220666292626
5326c6fed6d3ac6a3400000c	OBESITY;OBESE;obesity;obese	0.8618963017810378
52f129d92059c6d71c000009	One;ONE	0.08544591959935717
52eea509c8da89891000000d	mutations (using mSSCP and sequencing), genomic DNA	0.2642329927168593
516c3960298dcd4e51000073	members of the DNA methyltransferase enzyme family;Family Members;FAMILY MEMBER;members of the DNA methyltransferase (DNMT) protein family;member of the maintenance-type methyltransferase family	0.7268643862322611
516e7fda298dcd4e51000081	homocysteine, catalyzed	0.6934976363608936
52fe52702059c6d71c000078	centromere;Centromere;Centromeres;centromeres	0.7792079629760185
5311bf53e3eabad021000006	Pittsburgh Compound B;Pittsburgh compound B	0.7967479731680253
52fe52702059c6d71c000078	Suppressed;suppressed	0.5868416242937506
5358e067f1005d6b5800000b	directional migration	0.2633998002182953
5149199dd24251bc05000040	over 50 years	0.15112008708852262
515da6e2298dcd4e51000010	hydromorphone in 6 (20	0.4130174683898361
52e0c9a298d0239505000010	Strong methylation at H3 lysine;strong methylation at H3 lysine	0.5852526055474927
530cf4d5e2bfff940c000004	hunches about expected properties	0.10751175284853651
52eea509c8da89891000000d	LQT3;SCN5A	0.9748289612036465
52f129d92059c6d71c000009	Anterior pituitary aplasia	0.7996479343627808
52eea509c8da89891000000d	KCNE1;LQT5	0.9438880258947322
52eea509c8da89891000000d	KCNE2;LQT6	0.9560230896700816
53355befd6d3ac6a34000046	CAVITY;cavity	0.5829397928041933
516c3960298dcd4e51000073	homologous catalytic domains	0.40520188188336437
52eea509c8da89891000000d	CAV3;LQT9	0.8441333888287302
52eea509c8da89891000000d	LQT10;SCN4B	0.8435614929448487
52eea509c8da89891000000d	AKAP9	0.7969840935929572
515da6e2298dcd4e51000010	the last 72 hours	0.14283401595634992
52eea509c8da89891000000d	LQT12;SNTA1	0.8445373132251771
52eea509c8da89891000000d	KCNJ5;LQT13	0.8414015375518565
52e8e98298d0239505000020	catecholaminergic polymorphic ventricular tachycardia;CATECHOLAMINERGIC POLYMORPHIC VENTRICULAR TACHYCARDIA;Catecholaminergic polymorphic ventricular tachycardia	0.9912889430111388
52fe52702059c6d71c000078	fluorescent protein (GFP	0.428800725971069
52e8e98298d0239505000020	CPVT;CPVT)	0.7693181180340707
52eea509c8da89891000000d	SCN4B (locus name LQT10)	0.5036981076244235
53355befd6d3ac6a34000046	this context	0.1036838918155659
516c3960298dcd4e51000073	the closely related DNMT3B are	0.08127616919562691
5177def18ed59a060a000034	62 patients	0.25899188721130995
5358e067f1005d6b5800000b	PKCalpha	0.6569340488970437
53355befd6d3ac6a34000046	LiGenDock	0.8265807615268631
52eea509c8da89891000000d	HERG (human ether-a-go	0.4265568762662676
516ec97f298dcd4e51000087	method;methods;Method;Methods	0.01178315904292142
530cf4d5e2bfff940c000004	melanogaster;Melanogaster	0.5881305511410232
51434c74d24251bc0500000c	PRED-TMBB	0.9120024620561953
52e8e98298d0239505000020	CALR3;calreticulin 3;CALRETICULIN 3	0.8203338610643266
52e8e98298d0239505000020	HCM;hcm	0.6510265909073752
5149f494d24251bc0500004c	NALOXONE;naloxone	0.9974301574764971
5326c6fed6d3ac6a3400000c	Dyslipidaemia;dyslipidemia	0.7671171284278565
515da6e2298dcd4e51000010	medications by the oral;oral medications	0.11234593508856945
515da6e2298dcd4e51000010	ROUTE;route	0.09187439202215926
515da6e2298dcd4e51000010	SLEEP DISTURBANCE;sleep disturbance	0.20408441351893933
5149af96d24251bc05000046	cluster;Cluster	0.6060484959549999
516ec97f298dcd4e51000087	the widely used bootstrap method	0.021888216532946345
53355befd6d3ac6a34000046	the most potent noncovalent inhibitor of the native enzyme acetylcholinesterase (AChE	0.1704426921905391
5326c6fed6d3ac6a3400000c	Requirement;requirements;Required;required	0.08948304744076697
52f21b722059c6d71c00000b	positive;% Positive	0.18304268183750688
5358e067f1005d6b5800000b	EPS8;Eps8	0.906229390137596
52e8e98298d0239505000020	CPVT-related genes	0.16851158419243387
5311bf53e3eabad021000006	Neurodegeneration;neurodegeneration	0.6146690452547637
517818508ed59a060a000035	RTT;RETT SYNDROME;Rett syndrome	0.9997833312023503
517818508ed59a060a000035	found;in;In;Present;Found;present	0.05459717046190133
52fe52702059c6d71c000078	diverse DNA	0.2142312613725908
5358e067f1005d6b5800000b	a model	0.09610458236990461
52ebb2c698d0239505000029	epilepsy;EPILEPSY	0.7581788062022619
52ebb2c698d0239505000029	Subependymal giant cell astrocytomas;- subependymal giant cell astrocytoma;subependymal nodule (SN) - subependymal giant cell astrocytoma;Subependymal Giant Cell Astrocytoma;subependymal giant cell astrocytomas	0.9026299826774062
516ec97f298dcd4e51000087	Reproducibility;reproducibility	0.5903087694951255
51434c74d24251bc0500000c	strands of those proteins	0.09194505483384233
53357193d6d3ac6a34000047	tofacitinib;TOFACITINIB;tofacitinib);Tofacitinib	0.9999973358290473
51434c74d24251bc0500000c	OMPdb	0.6180635504634683
51585b28d24251bc0500008d	DNMT) 1;DNMT1;Dnmt1;. DNMT1;DNMT 1	0.9999999722372898
52ebb2c698d0239505000029	LYMPHANGIOLEIOMYOMATOSIS;lymphangioleiomyomatosis;Lymphangioleiomyomatosis	0.8649625007185222
5311bf53e3eabad021000006	concurrent AÎ² burden	0.4913648338322788
5358e067f1005d6b5800000b	Diaphanous-related formin dDia2	0.48423286559697476
517818508ed59a060a000035	Related;related	0.08823044441365928
51434c74d24251bc0500000c	Remote;remote	0.08566359214992372
515db20e298dcd4e51000014	cognitive-behavioural therapy;cognitive behavioral treatment;CBT);cognitive-behavioral treatment;CBT;Therapy, Cognitive Behavioral	0.9872374228762215
51585b28d24251bc0500008d	least;Less	0.08529794649190811
52ebb2c698d0239505000029	Rhabdomyoma	0.8324823825223011
530cf4c54a5037880c000008	Ibrutinib;ibrutinib;IBRUTINIB	0.9998641339801667
51434c74d24251bc0500000c	BOMP	0.8670768076916691
52ebb2c698d0239505000029	renal angiomyolipomas;Renal Angiomyolipoma	0.9658117046712745
51434c74d24251bc0500000c	22,23	0.6190265347699959
5149af96d24251bc05000046	the rosetta-stone method;the Rosetta Stone method	0.13752575084528962
52f21b722059c6d71c00000b	young ages	0.11786779486160143
516ec97f298dcd4e51000087	sequence;Base Sequence;Sequence;sequence-based	0.18436772886643601
516c3960298dcd4e51000073	recognition;Recognition	0.08529345838110539
51585b28d24251bc0500008d	PGC migration (E8.25	0.26541264944780285
530cf4d5e2bfff940c000004	either;Either	0.06739981324662822
53357193d6d3ac6a34000047	The preclinical pharmacokinetic (PK)/pharmacodynamic (PD) profile of tofacitinib	0.24165085678736298
52f21b722059c6d71c00000b	Human Epidermal growth factor Receptor (HER2) amplification (83	0.2271061435791609
5149af96d24251bc05000046	complex;Complex	0.13571813149090775
530cf4d5e2bfff940c000004	novel disease candidate	0.07912197986618219
53357193d6d3ac6a34000047	Clinical Treatment;clinical effects in the treatment	0.06405345883234752
530cf4c54a5037880c000008	the question of whether BTK kinase activity	0.04767031978314778
51434c74d24251bc0500000c	transFold	0.7806065780537432
51716a438ed59a060a00000a	protein coding genes;protein-coding genes;Protein coding gene	0.37264967633475155
530cf4c54a5037880c000008	kinase;Kinase	0.13759058746595051
5326c6fed6d3ac6a3400000c	Using	0.11731285955037841
515db20e298dcd4e51000014	Clinician ratings	0.26314368160363644
52f21e8f2059c6d71c00000c	BRCA1 dysfunction	0.6263036103188185
5358e067f1005d6b5800000b	Insulin receptor tyrosine kinase substrate p53 (IRSp53)	0.561487073206619
5149af96d24251bc05000046	mrs;MRS	0.6044352803348848
51716a438ed59a060a00000a	finding protein	0.07662004931059893
515db20e298dcd4e51000014	SERTRALINE;Sertraline;sertraline	0.7614959084677699
516ec97f298dcd4e51000087	jackknife	0.6495729380991286
5358e067f1005d6b5800000b	the N	0.25175447923445093
5149af96d24251bc05000046	FusionDB	0.6363127324170976
517818508ed59a060a000035	variant RTT	0.8084365283249108
51716a438ed59a060a00000a	Fgenesh++	0.8028186108532381
52ebb2c698d0239505000029	focal cortical dysplasia;Focal Dysplasia	0.7948057188421577
53357193d6d3ac6a34000047	RR for hypercholesterolaemia	0.2017199624360838
52f350042059c6d71c000010	1:5000	0.6572273975539571
52ebb2c698d0239505000029	cortical tubers;Cortical tubers	0.6473354980071575
5326c6fed6d3ac6a3400000c	different from other racial/ethnic groups;racial ETHNIC group differences	0.08566671462755807
5149af96d24251bc05000046	PLEX	0.6504987435908062
51716a438ed59a060a00000a	Fprom) for automatic identification	0.15916124836783066
530cf4d5e2bfff940c000004	complex diseases	0.1301334015425133
5326c6fed6d3ac6a3400000c	eq;EQ	0.6048431635290248
5149af96d24251bc05000046	Phydbac2	0.6450972373809336
530cf4c54a5037880c000008	B-cell receptor;B cell receptor	0.3342349117674852
5149af96d24251bc05000046	two additional non-similarity-based indicators	0.08022620349099213
51585b28d24251bc0500008d	Catalytic Domain;catalytic domain	0.27868093907794844
51434c74d24251bc0500000c	ProfTMB;PROFtmb	0.7244661657321977
5326c6fed6d3ac6a3400000c	non-Hispanic-blacks	0.4845283634753061
52f350042059c6d71c000010	0.01	0.8721656995116636
52ebb2c698d0239505000029	neurofibromas;Neurofibromas	0.8105547264766064
52ebb2c698d0239505000029	angiofibromas;Angiofibromas	0.7892872441854966
5149f494d24251bc0500004c	the primary cause	0.09407580516109065
5358e067f1005d6b5800000b	the beginning	0.09385603049925978
530cf4c54a5037880c000008	conducted;Behavior;behavior;Conduct	0.06431158436215328
5326c6fed6d3ac6a3400000c	MetS-related diseases	0.39984323798196125
51716a438ed59a060a00000a	GenScan;GEN-SCAN;GENSCAN	0.7176259410636533
5149af96d24251bc05000046	string;STRING	0.11813019990789969
53357193d6d3ac6a34000047	Clinical Trials, Phase III;phase III clinical trials;Phase 3 Study;phase 3 studies	0.3628940351011538
516ec97f298dcd4e51000087	no;NO	0.10325645662748323
52ebb2c698d0239505000029	mental retardation;MENTAL RETARDATION	0.4022864810084707
52ebb2c698d0239505000029	behavioral disorders;Behavioral disorders	0.18142428771321079
515db20e298dcd4e51000014	individual;Individual	0.17310411702954526
53061af558348c0f52000002	telomerase into senescent human cells	0.15812347723027675
517818508ed59a060a000035	55	0.7449197329550329
515db20e298dcd4e51000014	manualised cognitive-behavioural therapy (FRIENDS)	0.44809416522886913
51be411b047fa84d1d000006	detecting;detect;detects	0.011597434601589794
52ebb2c698d0239505000029	Refractory epilepsy;refractory epilepsy	0.8551190559008638
53061af558348c0f52000002	altered morphology;altered morphologic	0.2531349638930194
51434c74d24251bc0500000c	PROB;PROB)	0.6611242102004757
51585b28d24251bc0500008d	the loss	0.038549066880401814
5358e067f1005d6b5800000b	Our findings	0.10179667005534788
515db20e298dcd4e51000014	(aged 8 to 12)	0.4740032907221004
517137c18ed59a060a000001	PROTEIN;proteins;protein;PROTEINS	0.9982684996248825
515db20e298dcd4e51000014	Eight;eight	0.08305314085242181
52ef7786c8da898910000015	several;MULTIPLE;More;Multiple;more;multiple;Several	0.08010399033235507
51716a438ed59a060a00000a	the effectiveness	0.10240139344003134
51588bb2d24251bc05000091	Women;women	0.5793902330585161
51be411b047fa84d1d000006	LaTcOm	0.7385360570874061
5309f8f5970c65fa6b000001	Ras/Raf-prototypic oncogenes;Ras;RAS;ras;RAS/BRAF oncogenes;Ras oncogenes	0.9904669553723187
517137c18ed59a060a000001	HP1 beta;Cbx;CBX;HP1-BETA	0.8213069307260301
517137c18ed59a060a000001	HP1 alpha;HP1-ALPHA	0.8622102363304706
5311bf53e3eabad021000006	provides	0.11004517078402552
530cf4d5e2bfff940c000004	an expandable framework for gene prioritization	0.04024678260919269
51434c74d24251bc0500000c	BETAWARE	0.6623539548326524
515db20e298dcd4e51000014	the children in the individual versus 41%	0.04288950840852798
53592c1e9a4572de6f000002	3.4 mm;3 mm;3.0 mm	0.951547634354326
517137c18ed59a060a000001	Presence;presence	0.17963669901856422
51be411b047fa84d1d000006	sliding;Sliding	0.1099007376193006
51588bb2d24251bc05000091	body's;body	0.20139127827790218
530cf4d5e2bfff940c000004	highly connected genes	0.03854350028946567
515db20e298dcd4e51000014	referral;Referral	0.5887382730731332
530cf4d5e2bfff940c000004	the skewed degree distribution	0.0576212017534231
517818508ed59a060a000035	missense;Missense	0.6996107672698848
51716a438ed59a060a00000a	Species Specificity;species-specific	0.13936312675281268
5326c6fed6d3ac6a3400000c	world;World	0.09027737882290528
530cf4d5e2bfff940c000004	available interaction and disease association data	0.07899934448890533
515db20e298dcd4e51000014	the preference of the parents	0.035929104508695256
51716a438ed59a060a00000a	The gene prediction tools	0.026283163137017878
535d59349a4572de6f000009	iron-restricted anemias	0.5832413337769756
51434c74d24251bc0500000c	BOCTOPUS	0.7035151386609212
5309f8f5970c65fa6b000001	c-Abl;c abl	0.9881009839361886
517818508ed59a060a000035	1;1+	0.5999593802236559
52f350042059c6d71c000010	Down syndrome positive and 105 (0.4	0.19154801769773974
53357193d6d3ac6a34000047	Placebo;placebo	0.8165536103853169
51434c74d24251bc0500000c	TMBHMM	0.8341058240579929
535d59349a4572de6f000009	anemia of inflammation	0.3495881436955469
52f350042059c6d71c000010	52%	0.6145193127737419
51be411b047fa84d1d000006	%MinMax;MinMax	0.9589689982989306
5309f8f5970c65fa6b000001	c-Abl in replicative senescence and immortalization	0.23873214533456658
51716a438ed59a060a00000a	GeneID	0.7136971803163231
515db3d8298dcd4e51000015	10 nm	0.8274902004093755
517137c18ed59a060a000001	one;ONE	0.13818175823876086
51716a438ed59a060a00000a	GLEAN;Glean	0.6556954651399657
53357193d6d3ac6a34000047	the American College	0.09203315085230294
532b15ecd6d3ac6a34000014	BORTEZOMIB;bortezomib	0.7066347498927371
51716a438ed59a060a00000a	SN	0.6532613888200326
5309f8f5970c65fa6b000001	Raf;RAF	0.719692833074633
51716a438ed59a060a00000a	AUGUSTUS	0.6504759422538372
52f637972059c6d71c000025	pE96K mutation	0.3764496265151767
52f4f1d62059c6d71c00001c	compaction cardiomyopathy	0.24502952656375027
517137c18ed59a060a000001	the Chd2 gene	0.12160677722133117
5309f8f5970c65fa6b000001	Myc;MYC;(MYC	0.8982109738628669
5311bf53e3eabad021000006	subjects with mild cognitive impairment	0.08939420035189073
532b15ecd6d3ac6a34000014	DOXORUBICIN;doxorubicin	0.654019649443603
532b15ecd6d3ac6a34000014	VINCRISTINE;Vincristine	0.702862728236696
51434c74d24251bc0500000c	BTMX	0.653538427454682
51585b28d24251bc0500008d	Met1;MET1;met1	0.8078513487108121
532b15ecd6d3ac6a34000014	CISPLATIN;cisplatin	0.8111537042124801
517137c18ed59a060a000001	CHROMODOMAIN HELICASE DNA-BINDING PROTEIN 1;CHD1;CHD-1;Chd1;chromodomain helicase DNA-binding protein 1	0.9279129466053154
532b15ecd6d3ac6a34000014	ETOPOSIDE;Etoposide;etoposide	0.716726740871907
532b15ecd6d3ac6a34000014	fludarabine;FLUDARABINE	0.7113885642966574
517170c48ed59a060a00000d	25	0.6514665440080305
51588bb2d24251bc05000091	valproate;Valproate	0.7112071548154831
52f637972059c6d71c000025	MYH7	0.8168063852348315
5149af96d24251bc05000046	fdfBLAST	0.6445177673313401
51be411b047fa84d1d000006	PAUSE;pause	0.15763717144504122
52f4f1d62059c6d71c00001c	heart failure;FAILURE, HEART	0.2329596506924167
52f4f1d62059c6d71c00001c	SYNCOPE;syncope	0.5850752646604437
52f4f1d62059c6d71c00001c	Ventricular arrhythmias;ventricular arrhythmias	0.6721604231367497
5314c7afdae131f84700000a	HYPERHIDROSIS;hyperhidrosis	0.7762084674685669
52f4f1d62059c6d71c00001c	STROKE;stroke	0.08185126402749336
51434c74d24251bc0500000c	an accuracy of 84.2%	0.23179138077560385
5171a1498ed59a060a000012	. SF3B1;SF3B1	0.8963029760906
530cf4d5e2bfff940c000004	experimental data	0.1019456102464563
517137c18ed59a060a000001	CMT3;cmt3;DNA Methyltransferase;dna methyltransferase	0.8637568565875297
52f637972059c6d71c000025	NCCM with HCM	0.36101485520265386
5314c7afdae131f84700000a	Shapiro et al.	0.4369058330360564
53357193d6d3ac6a34000047	rheumatoid arthritis and collagen-	0.10432191839598616
530cf4e0c8a0b4a00c000004	Cardiomyopathy, Hypertrophic;hypertrophic cardiomyopathy	0.2066780797950352
51588bb2d24251bc05000091	exposure to valproate (5.6%	0.3574458488037685
52f4f1d62059c6d71c00001c	Hypertension, pulmonary;Pulmonary hypertension	0.6692703497624267
530cf4e0c8a0b4a00c000004	mice;mouse;Mouse, NOS;Mice	0.5331207594060048
5149af96d24251bc05000046	Context;context	0.2615565105513892
5171a1498ed59a060a000012	notch 1;NOTCH1	0.8689507462659198
51434c74d24251bc0500000c	TMBpro	0.6854756539956005
52f4f1d62059c6d71c00001c	11 mm	0.6378065761589936
5171a1498ed59a060a000012	XPO1	0.8106626907772824
5171a1498ed59a060a000012	myeloid differentiation primary response gene 88;MYELOID DIFFERENTIATION PRIMARY RESPONSE GENE 88;MYD88	0.9028952313370657
5171a1498ed59a060a000012	kelch-like 6;KELCH-LIKE 6	0.6298762085313816
530cf4e0c8a0b4a00c000004	(R403Q/;R403Q	0.7623041098001181
5149af96d24251bc05000046	InPrePPI	0.8715523747256707
5171a1498ed59a060a000012	KLHL6	0.6486464923331586
5311bf53e3eabad021000006	Progressive;progressive	0.09324356729682891
517137c18ed59a060a000001	chromodomain-helicase-DNA-binding protein;chromodomain helicase DNA binding protein	0.4943027546226846
532b15ecd6d3ac6a34000014	pingyangmycin lipiodol emulsion	0.825012381092625
51434c74d24251bc0500000c	TMBpro-CON) and tertiary	0.33981336788528127
5309f8f5970c65fa6b000001	SKP2;Skp2	0.8006090154188426
532b15ecd6d3ac6a34000014	Percutaneous intratumoral injection with pingyangmycin lipiodol emulsion	0.7110582876326441
517901bc8ed59a060a00003b	PD-1	0.6277818969944098
51be411b047fa84d1d000006	sliding window	0.0978378176321334
517137c18ed59a060a000001	60-80% of individuals	0.21633417416611259
532b15ecd6d3ac6a34000014	Emulsion;emulsion	0.5933926630053276
5149af96d24251bc05000046	the PPIs	0.13237296007635077
517a8bab8ed59a060a000040	best;Best	0.003991876656593785
5149af96d24251bc05000046	Our comparison	0.102064282837004
5171a1498ed59a060a000012	ZMYM3	0.821940499787142
5171a1498ed59a060a000012	MAPK1	0.7849943771096415
5171a1498ed59a060a000012	FBXW7	0.782959392058026
515db70c298dcd4e51000017	SKIN REACTION;skin reactions;reactions skin;skin reaction	0.22411515929630052
5171a1498ed59a060a000012	DDX3X;DDX3X)	0.7777184518835868
530cf4e0c8a0b4a00c000004	Allele;allele	0.750823506481845
52f895602059c6d71c000040	body weight;Body Weight;Body weight	0.25533821916304067
5314c7afdae131f84700000a	other causes	0.103041659504629
5171a1498ed59a060a000012	TP53	0.6218606829778772
5171a1498ed59a060a000012	ATM	0.6438468853056781
51585b28d24251bc0500008d	somatic divisions.In mammals	0.610657892593685
5309f8f5970c65fa6b000001	b-raf;BRAF	0.7345692613142092
51585b28d24251bc0500008d	the methylation patterns	0.02166203135569043
517a8bab8ed59a060a000040	4;[4];4+	0.6653404834714105
5309f8f5970c65fa6b000001	at;At	0.09493483009313972
5314c7afdae131f84700000a	Region;region	0.09413774567359622
51434c74d24251bc0500000c	a Z-value	0.1356593745493311
5171a1498ed59a060a000012	ATM in 9%	0.25671879121187785
52f4f1d62059c6d71c00001c	complete block;complete left branch conductive block	0.14172146574724462
517a8bab8ed59a060a000040	type 2 deiodinase	0.31232389669993077
52f4f1d62059c6d71c00001c	sick sinus syndrome;SICK SINUS SYNDROME	0.18628219295423243
5149af96d24251bc05000046	the computational methods for PPI prediction	0.02189439656580553
52f4f1d62059c6d71c00001c	Paroxysmal Supraventricular Tachycardia;paroxysmal supraventricular tachycardia	0.7961889097870707
5309f8f5970c65fa6b000001	suppress;suppresses	0.5613452644708926
5149af96d24251bc05000046	performance;Performance	0.08500288755840255
5314c7afdae131f84700000a	altered consciousness;Altered consciousness	0.11747244096403976
51434c74d24251bc0500000c	TMB-Hunt2;TMB-Hunt2)	0.5354187791840851
51588bb2d24251bc05000091	carbamazepine and two	0.1731481665253981
517a8bab8ed59a060a000040	iodothyronine deiodinase type III;type III iodothyronine deiodinase;type III deiodinase;type 3 deiodinase	0.8653730181076601
517539ca8ed59a060a000027	ARB2	0.8027743059123041
517539ca8ed59a060a000027	ARB1	0.6554077738549987
51434c74d24251bc0500000c	a website	0.2534249575145849
517539ca8ed59a060a000027	TRalpha1	0.7911804398443583
517137c18ed59a060a000001	CBX7	0.9105006084541535
51585b28d24251bc0500008d	cooperative activity	0.09984091877214958
51434c74d24251bc0500000c	TMB-Hunt	0.7350944517831811
5314c7afdae131f84700000a	patients with spontaneous periodic hypothermia and hyperhidrosis	0.2091626560177336
5309f8f5970c65fa6b000001	p21Cip1;p21CIP1	0.7409529571793467
52b2e409f828ad283c00000e	-- Schizophrenia;schizophrenia	0.8820236559734488
5314c7afdae131f84700000a	Cooling;cooling	0.0847421944508175
53357193d6d3ac6a34000047	multiple doses of CP-690,550	0.08035833035126498
517a8bab8ed59a060a000040	homeostasis of T(3) levels	0.27138358999814455
52f509232059c6d71c00001f	KCNJ2);KCNJ2;KIR2.1;Kir2.1	0.9977833438523822
530cf4e0c8a0b4a00c000004	an Arg403;an Arg 403	0.7126559012769472
51588bb2d24251bc05000091	a weaker, non-significant one	0.13173807946883268
52f895602059c6d71c000040	vital signs;vital sign;Vital Sign;Vital signs	0.21482446419997753
5309f8f5970c65fa6b000001	AKT;Akt	0.8460457456915282
515db70c298dcd4e51000017	severity;Severity	0.6003920637755423
517539ca8ed59a060a000027	Isoforms;isoforms	0.829710212707541
51585b28d24251bc0500008d	the addition of a methyl group	0.04205092726744351
530cf4e0c8a0b4a00c000004	Arg403Gln);Arg403Gln	0.7101413055892594
52f895602059c6d71c000040	antiterrorism activities	0.35844410597033755
517539ca8ed59a060a000027	TAK1	0.8249491736309176
52b2e409f828ad283c00000e	380	0.6813682529502161
51585b28d24251bc0500008d	methylation patterns at imprinted genes	0.05785817825812728
5311bf53e3eabad021000006	Early Detection;earlier diagnosis;early Alzheimer's disease detection;Early Diagnosis	0.1848031777820381
52f509232059c6d71c00001f	HERG;KCNH2 gene;KCNH2	0.9987940364236739
517539ca8ed59a060a000027	resulted;Result	0.06286729306660695
532f49f8d6d3ac6a34000035	Unconjugated estriol;ESTRIOL;unconjugated oestriol;unconjugated estriol;estriol	0.9965389128371497
51596a8ad24251bc0500009e	centrosome;Centrosome	0.9282213706539109
517a8bab8ed59a060a000040	euthyroidism and type-II	0.5248740870371149
51596a8ad24251bc0500009e	mother;Mother	0.08675099032661691
532f49f8d6d3ac6a34000035	(AFP);AFP	0.9253405731579416
5149af96d24251bc05000046	Rosetta Stone method;Rosetta stone" method)	0.3562491220436827
53357193d6d3ac6a34000047	INCB18424 targeting Jak1/2 and CP690,550 targeting Jak3	0.6384703608434029
52f895602059c6d71c000040	UTERINE CONTRACTIONS;uterine contractions	0.6992749956881944
52f895602059c6d71c000040	fetal heart signal	0.16925259030523185
53357c98d6d3ac6a3400004a	breast cancer;breast cancers;-- Breast Cancer	0.2781830444586228
52b2e409f828ad283c00000e	histamine;HISTAMINE	0.6523074786148721
517539e68ed59a060a000028	obtain;Obtain	0.08364140611221
532f49f8d6d3ac6a34000035	HCG;hCG	0.7674293987841739
53357c98d6d3ac6a3400004a	tumor suppressor p53;p53;P53;tumour suppressors p53	0.8663701371961208
5309f8f5970c65fa6b000001	p53 expression	0.3233621828032689
517a8bef8ed59a060a000041	Type 2 deiodinase	0.5107884737086203
51596a8ad24251bc0500009e	assembly;Assembly	0.09255923261305879
51596a8ad24251bc0500009e	inner;INNER	0.10799743643740801
517137c18ed59a060a000001	an important role	0.15032927660677176
5309f8f5970c65fa6b000001	HDAC2	0.8163260858180705
52f895602059c6d71c000040	ambulance services	0.33960640181250673
53189656b166e2b80600001c	Lewy neurites;Lewy neurite	0.9200461768177713
51585b28d24251bc0500008d	the establishment of methylation	0.01248294509127852
5147c088d24251bc05000026	small-cell lung cancer;LUNG CARCINOMA, SMALL CELL;small cell lung cancer;Lung cancer, small cell;Small-cell lung cancer;the diagnosis of small cell lung cancer;small-cell lung carcinoma;SCLC;SMALL CELL CANCER OF THE LUNG;SCLC)	0.9999999999999967
53189656b166e2b80600001c	alpha-synuclein;NACP;Alpha synuclein;Alpha-synuclein;alphaSYN;alpha-Synuclein	0.9999999999994813
53357c98d6d3ac6a3400004a	NRF2;nrf-2	0.7883416646451574
517539e68ed59a060a000028	ATP synthase subunit 6;subunit 6 of ATP synthase	0.5856018429927068
53189656b166e2b80600001c	alphaSYN protein fibrils	0.31063176319812447
515db70c298dcd4e51000017	Somnolence;DROWSINESS;somnolence;drowsiness	0.8596840351188992
517539e68ed59a060a000028	(ATPase-6	0.645977261703377
515db70c298dcd4e51000017	sedation	0.6903512904918296
52f895602059c6d71c000040	blood pressure control	0.35572073304126317
51596a8ad24251bc0500009e	a 135-kDa	0.4015724774956396
515db70c298dcd4e51000017	dizziness;DIZZINESS	0.785982294981252
530cf4e0c8a0b4a00c000004	familial hypertrophic cardiomyopathy (FHC) and sudden death	0.17325226987442055
515db70c298dcd4e51000017	MALAISE;malaise	0.6349800570582652
515db70c298dcd4e51000017	LASSITUDE;lassitude	0.6330955551343638
5149af96d24251bc05000046	current biochemical knowledge	0.14939519102867754
517539e68ed59a060a000028	VIc);VIc;VIC	0.6580760220443564
517137c18ed59a060a000001	Cbx2;CBX2	0.9592547377144488
52bf19f703868f1b06000002	Autosomal dominant;autosomal dominant	0.7867118737614566
53189656b166e2b80600001c	Degeneration;degeneration	0.591377624396055
53357c98d6d3ac6a3400004a	to;TO	0.0069211782008477725
517137c18ed59a060a000001	Reading;reading	0.10315009527471515
5311bf53e3eabad021000006	effectiveness;Effectiveness	0.09005825175386628
51585b28d24251bc0500008d	AT Gene;at imprinted genes	0.1252260193865405
52f509232059c6d71c00001f	genes KCNQ1;KCNQ1;KCNQ1 Gene	0.9833685090035486
5309f8f5970c65fa6b000001	Well;well	0.09106295983911487
51596a8ad24251bc0500009e	microtubule pair	0.2730036511943324
52f895602059c6d71c000040	step counting	0.10615884669419745
52bf19f703868f1b06000002	recessive cases	0.24837891281793906
53357c98d6d3ac6a3400004a	(BRCA)2;BRCA)2;BRCA2	0.9742051465675796
517539e68ed59a060a000028	mitochondrial (II and III) subunits of cytochrome-c oxidase	0.4081306614754899
5333f728d6d3ac6a34000041	Negatome	0.7132848326677491
517539e68ed59a060a000028	the thyroid state of the animals	0.05081505709328146
51585b28d24251bc0500008d	21]	0.7369010726291056
517a8c918ed59a060a000043	ENTEROVIRUS;Enteroviruses	0.7156289205999457
52f895602059c6d71c000040	electrocardiograms;Electrocardiograms	0.5844533170897189
52f895602059c6d71c000040	temperature	0.10598851945530863
52f895602059c6d71c000040	oxygen saturation;Oxygen saturation	0.2732929729318439
5309f8f5970c65fa6b000001	caveolin-1;Caveolin 1	0.9781047282417645
530cf4e0c8a0b4a00c000005	aortic root dilation;Aortic root dilation	0.9506124716722009
530cf4e0c8a0b4a00c000005	mitral valve prolapse;MITRAL VALVE PROLAPSE	0.9995811562082542
517a8c918ed59a060a000043	Enteroviruses (EV	0.6255074451285152
517a8c918ed59a060a000043	an important cause	0.04316422402952912
51766e438ed59a060a000031	SECIS Binding Protein 2;SBP2;SECIS binding protein 2	0.961818281695064
51766e438ed59a060a000031	tRNASec	0.8093694801199948
5311d130e3eabad021000009	's brain structural and gray/white matter volumetric responses	0.06517170589114937
51596a8ad24251bc0500009e	suggested;Suggest;suggesting	0.06631658750238172
51766e438ed59a060a000031	SECIS) element;SECIS element	0.40442433746207723
52f895602059c6d71c000040	SaO2);SaO2	0.6618038231271961
51596a8ad24251bc0500009e	a structural component	0.0946861993154391
5333f728d6d3ac6a34000041	Support Vector Machine	0.1494488809854375
517a8c918ed59a060a000043	adenovirus;ADENOVIRUS	0.6254231892626413
51766e438ed59a060a000031	SECp43	0.8679915547334037
5333f728d6d3ac6a34000041	problem;Problem	0.09860318068815388
530cf4e0c8a0b4a00c000005	mitral valve regurgitation;MITRAL VALVE REGURGITATION	0.7784550452985712
52f895602059c6d71c000040	ECG NOS;ECG	0.6106278819919748
530cf4e0c8a0b4a00c000005	aortic regurgitation;AORTIC VALVE REGURGITATION;aortic valves regurgitation;AORTIC REGURGITATION	0.9113642603498505
52f895602059c6d71c000040	breath rate;Breath rate	0.08413846615868521
51766e438ed59a060a000031	Sec synthase	0.6316202536906019
51766e438ed59a060a000031	L30	0.6376667206389205
53357c98d6d3ac6a3400004a	breast cancer gene 1 protein (BRCA1	0.06495265687246637
517137c18ed59a060a000001	Figure 1E	0.29763104512988875
52bf1af803868f1b06000008	missense or null-allele mutations	0.3451139503404786
5309f8f5970c65fa6b000001	protein (MAP) kinase cascade in murine fibroblasts	0.2388153980257607
5309f8f5970c65fa6b000001	MEK1;mek1	0.752374417117845
51766e438ed59a060a000031	SPS2	0.902287709982165
52f895602059c6d71c000040	ambulatory telemonitoring	0.6524420607276962
517a8cc68ed59a060a000044	rapidly progressive;Rapidly progressive	0.09227683957226257
5333f728d6d3ac6a34000041	protein complexes from protein-protein interaction data	0.010093271257451662
514a51c2d24251bc0500005c	Prolactinoma;prolactin (PRL)-secreting pituitary adenoma;PITUITARY ADENOMA, PROLACTIN SECRETING;PROLACTINOMA	0.6480135449271407
52f5417b2059c6d71c000024	BTBR T+tf/J (BTBR	0.7136463956803393
517a8cc68ed59a060a000044	inotropic agents;Inotropic agent	0.3762628857335919
515db70c298dcd4e51000017	partial seizures;Partial seizures	0.39358344193654954
53357c98d6d3ac6a3400004a	PROTEIN;protein	0.15612027882011564
517a8cc68ed59a060a000044	mechanical support	0.14492549137397634
515db70c298dcd4e51000017	one;ONE	0.08548874029428224
5309f8f5970c65fa6b000001	Signal;signal	0.08500829834130354
5333f728d6d3ac6a34000041	PEWCC;PEWCC)	0.7736086555464636
52f5417b2059c6d71c000024	Grin1;GRIN1	0.6267934200993796
52f5417b2059c6d71c000024	C58/J	0.662383023890052
530cf4e0c8a0b4a00c000005	2/3;2-3	0.5893797883997365
53189656b166e2b80600001c	a locus	0.32722763563195373
530cf4e0c8a0b4a00c000005	aneurysm;ANEURYSM	0.8027790850640968
530cf4e0c8a0b4a00c000005	cardiovascular abnormalities	0.6558132243183215
517137c18ed59a060a000001	the choanae	0.10582842554701988
51766e438ed59a060a000031	SPS1	0.8056488783641625
52bf1af803868f1b06000008	a familial cardiac arrhythmia	0.6654010983915217
52f5417b2059c6d71c000024	VPA600	0.6116291724469047
53357c98d6d3ac6a3400004a	BRC1-3	0.6553151880761015
514a51c2d24251bc0500005c	Follicles;follicles	0.6122316997165999
52f5417b2059c6d71c000024	600â€‰mg/kg valproic acid (VPA600)	0.5320556220146739
51766e438ed59a060a000031	SelD;SelD)	0.6932946686438785
517a8cc68ed59a060a000044	Astragalus Membranaceus;Astragalus membranaceus	0.5688325231193535
5309f8f5970c65fa6b000001	differentiation;Differentiation	0.8288320632255376
530cf4e0c8a0b4a00c000006	Cardiomyopathy, Hypertrophic;Hypertrophic cardiomyopathy;hypertrophic cardiomyopathy	0.9992342313437667
517137c18ed59a060a000001	ScoHET1	0.7045559712987636
5311d130e3eabad021000009	beta amyloid;Beta Amyloid	0.5547211900237914
52f89fc62059c6d71c000050	Squamous Cell Carcinoma;squamous cell carcinoma	0.4788834950241792
52bf1af803868f1b06000008	insight;Insight	0.08467725478897248
5333f728d6d3ac6a34000041	iPTMClust	0.8124678419116945
53357c98d6d3ac6a3400004a	estrogen/progesterone receptor;Estrogen+Progesterone receptor	0.7374081893334482
53357c98d6d3ac6a3400004a	human epidermal growth factor receptor 2;HER2;HER-2	0.9206407080377668
5147c088d24251bc05000026	332 pathologically diagnosed small cell lung cancer	0.07503657912907082
52f5417b2059c6d71c000024	Shank3-deficient mice	0.362619770050464
530a3e18970c65fa6b000005	Betaproteobacteria	0.7156337919605834
5311d130e3eabad021000009	the concentration	0.04064157751507235
5147c088d24251bc05000026	the symptoms	0.037658940990918904
530a3e18970c65fa6b000005	Firmicutes	0.8620797891377571
5333f728d6d3ac6a34000041	the quantity and identity of PTMs	0.10685262879611672
52f89fc62059c6d71c000050	formation	0.1022866499452457
5147c088d24251bc05000026	MUSCULAR WEAKNESS;muscular weakness	0.27991365573541194
530a3e18970c65fa6b000005	the Firmicutes	0.23763831334441668
530a3e18970c65fa6b000005	Geobacter	0.9954666240292301
52f89fc62059c6d71c000050	BHLHB3 gene overexpression inhibited colony formation of A549	0.17480445258835922
518ba4b5310faafe08000005	proton-pump inhibitors;Inhibitors, Proton Pump	0.7255234093323691
517843638ed59a060a000036	abundance;Abundance	0.5917674948629715
530a3e18970c65fa6b000005	Shewanella oneidensis	0.8117306937208922
53130a77e3eabad02100000f	Exposure NOS;exposure	0.10783141792494304
518ba4b5310faafe08000005	Immunosuppressive drugs;immunosuppressive drugs	0.21379529512332815
52f89fc62059c6d71c000050	non-small cell lung cancer;NSCLC;Carcinoma, Non-Small-Cell Lung;Lung cancer, non-small cell;of human non-small cell lung cancer;non-small cell lung carcinoma;Non-Small Cell Cancer of Lung	0.4805383426733205
52f5417b2059c6d71c000024	SYNGAP1	0.6706959051210644
518ba4b5310faafe08000005	fluticasone;FLUTICASONE	0.701740531423136
517843638ed59a060a000036	LINE-1	0.652638001365001
515bd543298dcd4e51000001	Loss;losses	0.0734691739522866
514a51c2d24251bc0500005c	cases of severe hyperprolactinemia	0.09497495271004608
52f5417b2059c6d71c000024	Tsc2f/-;	0.6034513589882207
517843638ed59a060a000036	L1	0.7141033251011869
514a51c2d24251bc0500005c	Very rare;very rare	0.20798028465751153
52bf1af803868f1b06000008	Catecholaminergic polymorphic ventricular tachycardia (CPVT;catecholaminergic polymorphic ventricular tachycardia (CPVT)	0.9088702582517104
517137c18ed59a060a000001	CDY	0.9381674187697264
52f5417b2059c6d71c000024	a risk factor for ASD	0.025553154687665117
517843638ed59a060a000036	Alu	0.643789333229983
517137c18ed59a060a000001	CDYL	0.8672432930566761
52f5417b2059c6d71c000024	NR1(neo	0.43971541787074847
515bd543298dcd4e51000001	H2	0.8396798335841524
517137c18ed59a060a000001	chromodomain Y chromosome	0.41940833621274914
5333f728d6d3ac6a34000041	protein complexes from the increasing amount	0.019579182663448474
518ba4b5310faafe08000005	EOSINOPHILIA;eosinophilia	0.6534235752990497
53130a77e3eabad02100000f	GH;Growth Hormone;growth hormone	0.9774526384387536
5147c088d24251bc05000026	channel disorder	0.12841031370626338
530a3e18970c65fa6b000005	Chryseobacterium;CHRYSEOBACTERIUM	0.5729388127448151
52f5417b2059c6d71c000024	MALTT	0.649200323390983
530a3e18970c65fa6b000005	Geobacteraceae;Family Geobacteraceae;family Geobacteraceae	0.9081580232004889
530a3e18970c65fa6b000005	responsible;Responsible	0.1786637944318261
515db70c298dcd4e51000017	hyperactivity;HYPERACTIVITY;HYPERACTIVE;hyperactive	0.7139153795932683
515db70c298dcd4e51000017	irritability;IRRITABILITY	0.6272644284054177
51585b28d24251bc0500008d	contrast to Dnmt3a and 3b	0.1686125612151911
515db70c298dcd4e51000017	agitation;AGITATION	0.6225054445951117
53130a77e3eabad02100000f	genetic syndromes with hypertrophic cardiomyopathy	0.1972250381174972
518cb4b5310faafe08000006	anti-thyroid drugs;antithyroid drugs;Antithyroid drugs	0.6627209036588222
52f5417b2059c6d71c000024	TS2-neo mouse	0.247908946558955
530db83b38c1322806000002	Sef;SEF	0.8716163241034987
53130a77e3eabad02100000f	cause	0.10865540590600971
514a51c2d24251bc0500005c	Pituitary microadenoma;pituitary microadenoma	0.5377476434516314
515db70c298dcd4e51000017	Aggressive behavior;Aggression;aggressive behavior;aggressive;aggression	0.1595052802282864
52f5417b2059c6d71c000024	Tbx1 heterozygous (HT) mice	0.2624821259956866
515bd543298dcd4e51000001	Frequencies;frequencies	0.09995849488068424
53130a77e3eabad02100000f	to;TO	0.11168862962494697
517137c18ed59a060a000001	mRNA	0.7005917591702209
530db83b38c1322806000002	NF-ÎºB	0.9598443559118903
518cb4b5310faafe08000006	Corticosteroids;corticosteroids	0.7056522334335286
511a3573df1ebcce7d000018	15	0.9911645349117016
52f89fc62059c6d71c000050	HCT 116) cancer cell lines	0.3245584317164602
530db83b38c1322806000002	Inhibitory;inhibitory	0.7769520940576397
530db83b38c1322806000002	nuclei;NUCLEUS;nucleus	0.6781574073226411
5333f728d6d3ac6a34000041	PROCOMOSS	0.6608464834904445
515db70c298dcd4e51000017	Defiance;defiance	0.5881417523119652
5333f728d6d3ac6a34000041	PPI network	0.39239839535211424
52f5417b2059c6d71c000024	(Dp(11)17/;Dp(11)17/+)	0.515273037106546
53357ca0d6d3ac6a3400004b	spleen tyrosine kinase;Spleen Tyrosine Kinase	0.9999819731954384
53189656b166e2b80600001c	play;Play	0.0838050347963502
515db70c298dcd4e51000017	oppositional behavior	0.28002403362929223
51585b28d24251bc0500008d	exact;Exact	0.08517305664075835
518cb4b5310faafe08000006	lithium;LITHIUM	0.7756653750160415
530a3e18970c65fa6b000005	Geobacteraceae feoB transcripts in groundwater samples	0.23718855565726357
53357ca0d6d3ac6a3400004b	Diffuse;diffuse	0.59032072926903
5147c088d24251bc05000026	the majority	0.03979812794316442
5333f728d6d3ac6a34000041	EPOF	0.8447687572116289
53357ca0d6d3ac6a3400004b	the Syk inhibitor fostamatinib;the Syk inhibitor Fostamatinib	0.48354585562283314
530a3e18970c65fa6b000005	Geobacter uraniireducens	0.9487581900526065
5333f728d6d3ac6a34000041	Eagle;EAGLE	0.6112913772498071
5333f728d6d3ac6a34000041	/mcL;MCL	0.9473843568426593
5333f728d6d3ac6a34000041	IPCA	0.8280076283201755
52bf1af803868f1b06000008	autosomal-recessive CPVT	0.7643121857009454
53130a77e3eabad02100000f	recommendations	0.11583551169381831
5333f728d6d3ac6a34000041	CMC	0.8046029350414667
5333f728d6d3ac6a34000041	NFC	0.6219982007342748
51487ef9d24251bc05000031	. Entacapone;entacapone;ENTACAPONE;Entacapone	0.9996678989657773
5150f401d24251bc05000075	Elonza	0.6553476162857087
5333f728d6d3ac6a34000041	DPClus	0.6403839804237128
5333f728d6d3ac6a34000041	MCODE;MCode	0.7852231276461394
5333f728d6d3ac6a34000041	SPICi	0.6530616604074269
5333f728d6d3ac6a34000041	CPM	0.6853639746618233
5333f728d6d3ac6a34000041	Core-Attachment	0.4876022302861857
52bf1b0a03868f1b06000009	Inheritance of a pair of alleles of an autosomal recessive;Autosomal recessive;Autosomal Recessive Inheritance;Autosomal recessive inheritance;autosomal-recessive pattern of inheritance;autosomal recessive inheritance;autosomal recessive	0.999998527068115
5319a6c9b166e2b806000022	These inhibitors	0.22940613744525576
53357ca0d6d3ac6a3400004b	this phase 2 study	0.11021293427474266
530a3e18970c65fa6b000005	strain Rf4T	0.2455232662200594
52bf1b0a03868f1b06000009	copper;COPPER	0.8100642828198907
5333f728d6d3ac6a34000041	ProRank	0.690657364920943
51585b28d24251bc0500008d	small interfering RNA-mediated knockdown	0.23041802541975206
5333f728d6d3ac6a34000041	CFinder	0.6891680273840605
5333f728d6d3ac6a34000041	ClusterONE	0.6929621570835713
5319a6c9b166e2b806000022	ZD6474	0.7619805996641332
5319a6c9b166e2b806000022	SU11248	0.7595371110321373
5319a6c9b166e2b806000022	AEE 788	0.841754875944098
52bf1b0a03868f1b06000009	excessive copper deposition	0.35911463612014544
52f89fd32059c6d71c000051	ACF/WCRF complex;ACF complex	0.8267190083329905
5319a6c9b166e2b806000022	sorafenib;SORAFENIB	0.6999260996730914
5319a6c9b166e2b806000022	VATALANIB;vatalanib	0.6988340962762022
5319a6c9b166e2b806000022	AG-013736;AG 013736	0.7105479857069171
53130a77e3eabad02100000f	growth hormone deficiency and hypoglycemia	0.24604897671072082
52f88d292059c6d71c000036	GHD;Growth hormone deficiency;growth hormone (GH) deficiency;growth hormone deficiency	0.8472271604338999
5333f728d6d3ac6a34000041	Spectral	0.6260330325462751
515de748298dcd4e51000023	In	0.12304478903420257
511a4d391159fa8212000003	DRM	0.9027968164208493
51487ef9d24251bc05000031	100;100%	0.6059769692948617
5333f728d6d3ac6a34000041	RNSC	0.5685696375929588
517137c18ed59a060a000001	preferential binding affinity	0.6201950914704212
51487ef9d24251bc05000031	use	0.012599494000422515
53130a77e3eabad02100000f	Second;second	0.08968730022466846
51596a8ad24251bc0500009e	centrosome;Centrosome	0.9290713518281082
52f89fd32059c6d71c000051	characterized;Characterized	0.10962526068416216
52f89fd32059c6d71c000051	Gfi-1b	0.7105179944354804
52f89fd32059c6d71c000051	FOG-1	0.9759630956547196
52f89fd32059c6d71c000051	Tal1;TAL1;TAL-1	0.881591223659845
515de748298dcd4e51000023	contrast;Contrast	0.09253470236301001
511a4d391159fa8212000003	suggests;Suggest;suggesting	0.08250818629310828
5333f728d6d3ac6a34000041	HKC	0.6539743599624762
517137c18ed59a060a000001	Swi6	0.7001054931189805
52f89fd32059c6d71c000051	Ldb1;Ldb-1;LDB1	0.8352065888659319
52bf1b0a03868f1b06000009	such copper accumulation in WD	0.22807735871771734
515de748298dcd4e51000023	Dermatofibrosarcoma protuberans (DFSP);Dermatofibrosarcoma protuberans (DFSP	0.7021646690043126
517137c18ed59a060a000001	Chp1;CHP1	0.8660706719763807
52bf1b0a03868f1b06000009	Mortality;mortality	0.08035689461074362
530a3e18970c65fa6b000005	Anaeromyxobacter dehalogenans	0.6131986716118484
511a4d391159fa8212000003	Meet;MET	0.7540203412797328
530db83b38c1322806000002	Kappa;kappa	0.6183776949606328
515de748298dcd4e51000023	tumor size;Tumor size	0.16449409731975423
52bf1b0a03868f1b06000009	a treatable movement disorder with autosomal recessive inheritance	0.2689494134723461
52bf1b0a03868f1b06000009	hemochromatosis;HEMOCHROMATOSIS	0.8277228498258684
52f89fd32059c6d71c000051	GATA-1/Gfi-1b with the suppression	0.30743642981996044
517137c18ed59a060a000001	RITS complex	0.2884554355789365
52f89fd32059c6d71c000051	cell proliferation and GATA-1/FOG-1/MeCP1 with the repression	0.10475620139457593
517137c18ed59a060a000001	cpSRP43	0.8365651049084388
531464a6e3eabad021000014	XK gene;XK LOCUS;Xk gene;XK locus;XK	1.0
53357ca0d6d3ac6a3400004b	R-406;R406);R406	0.9399971404682012
52f89fd32059c6d71c000051	LMO2-C	0.9189358286108572
5319a708b166e2b806000024	the ubiquitin-proteasome pathway;The ubiquitin-proteasome pathway	0.6691768978017019
531464a6e3eabad021000014	responsible;Responsible	0.14088238414389614
530a3e18970c65fa6b000005	iron-reducing;iron reducing	0.10312093829902486
52f89fd32059c6d71c000051	LDB1 protein	0.09655250438113218
5319a708b166e2b806000024	multimodal therapeutic approaches	0.37284298813641975
51596a8ad24251bc0500009e	Chlamydomonas reinhardtii	0.6359789028897556
52f89fd32059c6d71c000051	PIAS3	0.8209431077435001
530a3e18970c65fa6b000005	the iron	0.09333453281966751
515bf6d6298dcd4e51000004	nasopharyngeal carcinomas;NASOPHARYNGEAL CARCINOMA	0.8031047391438427
52f89fd32059c6d71c000051	ETS	0.7096265573216323
515bf6d6298dcd4e51000004	colon adenocarcinomas;COLON ADENOCARCINOMA	0.7975243001635438
530a3e18970c65fa6b000005	Pseudomonas aeruginosa;PSEUDOMONAS AERUGINOSA	0.7215663941346834
5333f728d6d3ac6a34000041	NWE	0.6142218359159949
52f89fd32059c6d71c000051	RUNX1	0.6299381549570917
517137c18ed59a060a000001	CReMM	0.7611036420872145
515bf6d6298dcd4e51000004	three;Three	0.14267935417463773
518cb5ab310faafe08000008	amoxicillin;AMOXICILLIN	0.5861778660465953
530db83b38c1322806000002	B2)	0.6120344254057272
5333f728d6d3ac6a34000041	a cluster	0.0992380501375859
518cb5ab310faafe08000008	rifabutin;RIFABUTIN	0.6521003902476747
515de748298dcd4e51000023	December 2008)	0.687226277666097
51487ef9d24251bc05000031	a complement	0.25651322984901764
531464a6e3eabad021000014	a novel XK splice site mutation	0.14102664034012746
518cb5ab310faafe08000008	metronidazole;METRONIDAZOLE	0.6994561221099852
515bf6d6298dcd4e51000004	BM infiltration	0.7348824326414455
52f89fd32059c6d71c000051	these two factors	0.07715672212982655
51585b28d24251bc0500008d	an important role in the gene-silencing network	0.0442349606308654
5333f728d6d3ac6a34000041	CP-DR	0.7387371971022426
51487ef9d24251bc05000031	levodopa concentration in plasma and brain	0.1771675133407286
52bf1b0a03868f1b06000009	their clinically asymptomatic relatives	0.32346692534538707
51487ef9d24251bc05000031	tolcapone;Tolcapone;TOLCAPONE	0.9765947344349718
52f89fd32059c6d71c000051	Ski;Ski's	0.5011416465608888
52f88d292059c6d71c000036	Referred;referred	0.07653481784290617
5312280ce3eabad02100000a	extra chromosomal material on 6p	0.08840197769097702
515ffc2b298dcd4e51000035	Aspergillus terreus	0.9999984131679127
517137c18ed59a060a000001	wide;Broad;Wide;broader	0.08655248180797129
5333f728d6d3ac6a34000041	PIPE	0.2334599824571635
52f89fd32059c6d71c000051	PU.1	0.8905902492937493
52f88d292059c6d71c000036	-old male adolescent	0.11173058767135885
52f89fd32059c6d71c000051	zinc finger transcription factor	0.25033129677198945
515870cdd24251bc0500008f	KPC	0.9994232061628607
515870cdd24251bc0500008f	VIM;vim;VIM-	0.9596250499949481
52f89fd32059c6d71c000051	EKLF	0.6353517867725781
52f89fd32059c6d71c000051	SP1	0.620107959065774
52f89fd32059c6d71c000051	CBP/p300	0.661550856159237
511a4d391159fa8212000003	CMT	0.6517738421776742
52bf1cb303868f1b0600000b	syndactyly;symphalangism;Symphalangism;SYNDACTYLY	0.9477005242275107
515870cdd24251bc0500008f	The most frequent carbapenemases in Enterobacteriaceae	0.004938091997401246
5312280ce3eabad02100000a	17;17%	0.7152068019581482
515870cdd24251bc0500008f	NDM;NDMS	0.8590615069094232
515870cdd24251bc0500008f	IMP-;IMP;IMP)	0.6858281720762857
530c844e970c65fa6b000014	Leigh syndrome;Leigh's syndrome;LEIGH SYNDROME	0.6100568412239041
53358cd2d6d3ac6a3400004e	Tay-syndrome;trichothiodystrophy);Tricho-thiodystrophy;Tay syndrome;trichothiodystrophy;TAY SYNDROME	0.9999963977626477
515de572298dcd4e51000021	UMPIRE)	0.634917773380593
5312280ce3eabad02100000a	characterized;Characterized	0.08562717995449601
517137c18ed59a060a000001	TgMYST-A	0.34617543800782735
531464a6e3eabad021000014	better;Better	0.10385658830552025
515870cdd24251bc0500008f	matrix-assisted laser desorption ionization-time of flight mass spectrometry;Matrix-Assisted Laser Desorption/Ionization-Time of Flight Mass Spectrometry	0.3586438829068461
515ffc2b298dcd4e51000035	the coexistence	0.10529067861269313
53358cd2d6d3ac6a3400004e	ICHTHYOSIS;ichthyosis	0.8607036947549987
51bdb644047fa84d1d000001	POM121;Pom121	0.9995182060349604
52fa6ac72059c6d71c000055	Transcriptional Repressor;repressor for transcription;transcription repressor;Repressor;repressor;transcriptional repressor;Transcription Repressor	1.0
515870cdd24251bc0500008f	OXA-48	0.69183536893315
517137c18ed59a060a000001	MRG15;. MRG15	0.9987448365310051
515870cdd24251bc0500008f	MBL	0.6513622712859513
52bf1cb303868f1b0600000b	tendon insertions;Tendon insertion	0.5665951762346192
52bf1cb303868f1b0600000b	Neurovascular Bundle;neurovascular bundles	0.6671992231452537
52f88d292059c6d71c000036	Presence;presence	0.10721357465847262
51387022bee46bd34c000002	mutational;Mutation	0.5904266247370817
52bf1cb303868f1b0600000b	extrinsic tendon insertions	0.6191394014378209
51387022bee46bd34c000002	development;aspects of development;development aspects	0.4924883934194913
51bdb644047fa84d1d000001	NDC1;Ndc1;Net3;NET3	0.9997469124084534
51487ef9d24251bc05000031	several kinetic models of FDOPA uptake	0.1461918157229135
52bf1cb303868f1b0600000b	long and ring fingers	0.08677034993955465
515870cdd24251bc0500008f	CEPHALOSPORINS;cephalosporins	0.7492304169518831
51bdb644047fa84d1d000001	contains;contain;Containing;containing	0.2552524252751641
51387022bee46bd34c000002	Mammal;mammalian;mammal;Mammalian	0.8523583422167643
51bdb644047fa84d1d000001	50%;50	0.593096468046772
52bf1cb303868f1b0600000b	POLYDACTYLY;polydactyly	0.592675402749753
5312280ce3eabad02100000a	72 Japanese MMD patients with 45 Japanese controls	0.1226583553760914
5319a708b166e2b806000024	their packaging in the form	0.04638295579269513
515ffc2b298dcd4e51000035	Aspergillus niger	0.9097712854846502
515870cdd24251bc0500008f	ChromID ESBL	0.6518285890667905
5162c8a8298dcd4e51000047	POP2;Pop2	0.8213521591794557
5162c8a8298dcd4e51000047	PARN	0.8986649281392388
52f88d292059c6d71c000036	the elevated levels of prolactin	0.15828066832941912
5162c8a8298dcd4e51000047	PAN2	0.8458132410041261
51487ef9d24251bc05000031	)-5-chloro-2-pyridine carboxamide HC1)	0.4636355839917061
53357ca0d6d3ac6a3400004b	DOUBLE BLIND;double-blind	0.19260516009613
52fc94db2059c6d71c000074	bapineuzumab;BAPINEUZUMAB	0.9920570051480411
5148e1d6d24251bc0500003a	neurofibromatosis I gene;neurofibromatosis type 1 (NF1) gene;NFI gene;von Recklinghausen neurofibromatosis;gene for von Recklinghausen neurofibromatosis type 1;Neurofibromatosis 1 Gene;neurofibromatosis-1 gene;Neurofibromatosis Type 1 (NF1) gene;von recklinghausen's neurofibromatosis;neurofibromatosis type 1 gene;NF1 Gene;NF1 gene	0.9998882348514091
5162c8a8298dcd4e51000047	Nocturnin;nocturnin	0.8920536848180732
52bf1cb303868f1b0600000b	% total;total	0.09812431705640501
531464a6e3eabad021000014	Antigens;antigens	0.5869360705717082
5312280ce3eabad02100000a	cardiologic and ophthalmologic evaluation	0.23192529410443966
52fc94db2059c6d71c000074	based;Based	0.08324723412950569
51bdb644047fa84d1d000001	GP210;gp210;Gp210	0.9999147578556214
517137c18ed59a060a000001	ANIMAL;animal	0.13464972106178094
51387022bee46bd34c000002	regulatory sequences	0.0952028835968241
5148e1d6d24251bc0500003a	Chromosome 17;chromosome 17	0.9988975047563057
517137c18ed59a060a000001	macromolecular complexes;Macromolecular Complexes	0.38580860672692485
52bf1cb303868f1b0600000b	early bilateral separation	0.14732643508784563
5162c8a8298dcd4e51000047	CCR4;Ccr4	0.8384821610602945
530cefaaad0bf1360c000002	Sample;samples	0.15284592920007176
53357ca0d6d3ac6a3400004b	demonstrates;Demonstrates	0.07760697825646376
53357ca0d6d3ac6a3400004b	rapid;Rapidly;Rapid;rapidly	0.06787564160984662
530cefaaad0bf1360c000002	Nucleus Accumbens;nucleus accumbens	0.9815252801848208
530cefaaad0bf1360c000002	subgenual cingulate gyrus	0.6266064201569459
515870cdd24251bc0500008f	GES	0.8228840769785136
515870cdd24251bc0500008f	IMI;imi	0.8704660456692112
52bf1cb303868f1b0600000b	Craniofacial anomalies;craniofacial anomalies	0.6960122985533234
52fc94db2059c6d71c000074	SOLANEZUMAB;Solanezumab;Solanezumab's;solanezumab;solanezumab)	0.9262793174057825
52fc94db2059c6d71c000074	two;Two	0.1622737928762158
5162c8a8298dcd4e51000047	poly(A;Poly A	0.7279185161924604
53358cd2d6d3ac6a3400004e	Increase;increase	0.07709429389043582
515ffc2b298dcd4e51000035	OXYGEN;oxygen	0.08394813374431542
51387022bee46bd34c000002	multiple regulatory inputs	0.09402973260735671
51bdb644047fa84d1d000001	localize;localizes	0.7191635156550374
530cefaaad0bf1360c000002	medial forebrain bundle;Medial Forebrain Bundle	0.7990705752790849
530cefaaad0bf1360c000002	habenula);Habenula;habenula	0.8324880867454381
515ffc2b298dcd4e51000035	aconitate decarboxylase;Aconitate decarboxylase	0.750008435098829
515de572298dcd4e51000021	amlodipine co-administration with atorvastatin;AMLODIPINE/ATORVASTATIN	0.6409125462676077
5312280ce3eabad02100000a	Xq	0.6568392268990357
515ffc2b298dcd4e51000035	citric acid producing fungus A	0.16712986912707545
5312280ce3eabad02100000a	The small number	0.04939758509924025
5312280ce3eabad02100000a	patient age	0.10302112112605101
52fc94db2059c6d71c000074	ponezumab;PONEZUMAB	0.7152075228237478
52fc94db2059c6d71c000074	gantenerumab;GANTENERUMAB	0.7052274452597752
515ffc2b298dcd4e51000035	Ustilago maydis;USTILAGO MAYDIS	0.5765367600497616
515870cdd24251bc0500008f	vim-1-carbapenemase-	0.18249205122154108
530cefaaad0bf1360c000002	MD	0.666557195271707
5162c8a8298dcd4e51000047	a deoxy nucleotide substrate with a sequence	0.15146749146481336
53357ca0d6d3ac6a3400004b	SYK activity;Syk activity	0.3929811244924554
52fc94db2059c6d71c000074	IMMUNOTHERAPY;immunotherapy	0.5895669486704561
530cefaaad0bf1360c000002	areas	0.1878374050278051
5148e1d6d24251bc0500003a	our joint analysis	0.10796086858707414
5312280ce3eabad02100000a	The gene responsible	0.046645695556957995
52fc94db2059c6d71c000074	passive administration	0.43174961726317423
51387022bee46bd34c000002	FISH;Fish	0.09193060200207094
53357ca0d6d3ac6a3400004b	SU6656	0.8011336541012624
5148e1d6d24251bc0500003a	the recombination fractions for the closest markers	0.06455487907165434
515870cdd24251bc0500008f	NMC-	0.3793373194116856
517137c18ed59a060a000001	dMi-2	0.7668815102674711
52bf1cb303868f1b0600000b	the average, among them	0.08015691678994331
530cefaaad0bf1360c000002	Functional inhibition	0.2477683538935523
52bf1d6003868f1b0600000e	type 1;type I;Type I;Type 1	0.9854701349509838
515de572298dcd4e51000021	GEMINI	0.6536906097837488
52bf1d6003868f1b0600000e	type 2;Type 2;type II;types 2;Types 2;Type II	0.9994502971688767
52bf1d6003868f1b0600000e	type 3;Type III;Type 3;type III	0.8757146411697379
53358cd2d6d3ac6a3400004e	Other features of this syndrome	0.01674388538350249
51bdb644047fa84d1d000001	Suggest;suggesting	0.0848402112865654
515de572298dcd4e51000021	JEWEL 1	0.7285796914628166
51bdb644047fa84d1d000001	hNDC1	0.7937544982877879
51595fb0d24251bc0500009c	PARP1	0.8271173616116694
51595fb0d24251bc0500009c	CD44	0.719575107840343
515de572298dcd4e51000021	JEWEL 2	0.5989535217410523
52f893f92059c6d71c00003c	omega-3 fatty acid supplementation;Omega 3 fatty acid supplementation	0.5028693428110211
530cefaaad0bf1360c000002	After;after	0.07177115099383928
5335c7f2d6d3ac6a34000051	empagliflozin	0.7671583587809956
515de572298dcd4e51000021	CAPABLE54)	0.6264445889985243
530cefaaad0bf1360c000002	ventral caudate nucleus	0.7969949244845022
51595fb0d24251bc0500009c	ER	0.6136957578500315
515de572298dcd4e51000021	CUSP;Cusp	0.6532430359752818
52bf1d6003868f1b0600000e	extreme proptosis	0.31019902731797516
52bf1d6003868f1b0600000e	a cloverleaf skull	0.14564416789210283
530cefaaad0bf1360c000002	the start	0.08426472985016924
51595fb0d24251bc0500009c	Mage-A4	0.8149754639850615
52f893f92059c6d71c00003c	NCT00794079	0.6754987672867965
51475d5cd24251bc0500001b	good qualitative agreement	0.1512473703926922
5335c7f2d6d3ac6a34000051	Sodium glucose co-transporter 2;SGLT2;sodium-glucose cotransporter 2;SODIUM-GLUCOSE TRANSPORTER 2	0.788825473158527
51bdb644047fa84d1d000001	The number and orientation of the transmembrane segments	0.014531180295981777
5171651e8ed59a060a000009	kallikrein-related peptidase 3, human;human kallikrein-related peptidase 3;Human kallikrein-related peptidase 3	0.8313612486950035
53357ca0d6d3ac6a3400004b	this time	0.10839707465086022
5335c7f2d6d3ac6a34000051	focusing	0.1079027483426306
5171651e8ed59a060a000009	single;Single	0.09177933209632831
5162c8a8298dcd4e51000047	Caf1p/Pop2p interaction	0.39601555321273185
515de572298dcd4e51000021	TOGETHER;Together	0.09543489853604266
5171651e8ed59a060a000009	hK3	0.6602181755827978
530e1c985937551c09000004	Deafness;DEAFNESS;deafness	0.728926665757001
530e1c985937551c09000004	Onychodystrophy;onychodystrophy	0.8486431378778343
530e1c985937551c09000004	Osteodystrophy;osteodystrophy	0.766885757468257
52f896d62059c6d71c000046	Dysmnesia;loss of memory;LOSS OF MEMORY;MEMORY LOSS;dysmnesia;memory loss	0.8329360583069508
530e1c985937551c09000004	mental retardation;MENTAL RETARDATION	0.3539812663808012
531464a6e3eabad021000014	Comprise;comprised	0.08169509022053417
51716e808ed59a060a00000b	Which	0.004892408818200848
530cefaaad0bf1360c000003	ALEMTUZUMAB;Alemtuzumab's;Alemtuzumab);Monoclonal Antibody CD52;alemtuzumab;Anti-CD52 Monoclonal Antibody;Alemtuzumab;anti-CD52 monoclonal antibody;monoclonal antibody targeting CD52;CD52 monoclonal antibody	0.9999999999777591
51475d5cd24251bc0500001b	following;Following	0.09531377314418064
530e1c985937551c09000004	SEIZURES;seizures	0.6411607019499367
5162c8a8298dcd4e51000047	rich repeats	0.10133496364082491
51716e808ed59a060a00000b	Ixodes ricinus	0.8100201963870236
5312280ce3eabad02100000a	the proximal breakpoint	0.2051787180141861
51595fb0d24251bc0500009c	LSR	0.8425281861892534
51595fb0d24251bc0500009c	RAB25	0.8228568318920557
51bdb644047fa84d1d000001	form;Form	0.08312544993550257
51595fb0d24251bc0500009c	S100A14	0.8264684701012014
531464a6e3eabad021000014	the Kell-protein binding site	0.24552271078828197
51475d5cd24251bc0500001b	Nanocrystals;nanocrystals	0.9329868002242658
515de572298dcd4e51000021	IMPACT	0.13651692334705925
51595fb0d24251bc0500009c	MUC1	0.641901696483462
533675ced6d3ac6a34000056	histone variants	0.2116864270792292
51716e808ed59a060a00000b	Wildlife;wildlife	0.11784132484564326
5148e1d6d24251bc0500003a	Cutaneous neurofibroma;cutaneous neurofibromas	0.8335951827801737
533675ced6d3ac6a34000056	H2AZ;H2A.Z	0.9325948504164938
51595fb0d24251bc0500009c	Hsp90;HSP90	0.7477262500844258
5312280ce3eabad02100000a	tissue inhibitor of metalloproteinase (TIMP) 4;tissue inhibitor of metalloproteinase 4	0.6726298394854305
52f8995b2059c6d71c00004a	Five;five	0.12429924732221471
515de572298dcd4e51000021	TIP-2;TIPS-2	0.7570621142567417
52f8995b2059c6d71c00004a	iron;IRON	0.10662466196040224
5148e1d6d24251bc0500003a	inherited diseases	0.28885839204377867
51387022bee46bd34c000002	Association, developmental;association with developmental	0.17856884819848173
533675ced6d3ac6a34000056	H2AX;histone variant H2AX;Histone H2AX;H2A.X;-H2AX;Histone variant H2AX;histone H2AX	0.9993210427543886
530f900ee3eabad021000003	Thyroid, NOS;thyroid	0.7081534316881465
5312280ce3eabad02100000a	a protein	0.19534359064149434
5319a724b166e2b806000025	X-linked spinal and bulbar muscular atrophy (SBMA)	0.538196738015112
515de572298dcd4e51000021	TIPS	0.9224144224282285
51bdb644047fa84d1d000001	4 - 6;4-6	0.6185169282044362
51475d5cd24251bc0500001b	Molecular imaging;imaging of biological molecules;Molecular Imaging;molecular imaging	0.837333369394197
531464a6e3eabad021000014	proven;Proven	0.09753452445516984
5319a724b166e2b806000025	dentatorubral-pallidoluysian atrophy (DRPLA)	0.6522697789696307
51475d5cd24251bc0500001b	pump--probe experiments	0.2532701806667006
52f8995b2059c6d71c00004a	frequent;Frequent	0.2301926147273171
51595fb0d24251bc0500009c	Vimentin;vimentin	0.8535788641427272
51bdb644047fa84d1d000001	perinuclear space;Lumen of nuclear envelope;Perinuclear Space;lumen of the nuclear envelope	0.5376854436969976
530cefaaad0bf1360c000003	the relapse rate	0.1433682143724218
52f8995b2059c6d71c00004a	MEIS1	0.8322719423670344
533c2a55c45e133714000003	Yap1;YAP1;YAP;Yki;YKI	0.7946904573052022
52bf1d9e03868f1b06000010	RANKL;Receptor Activator of Nuclear Factor Kappa B Ligand;Receptor activator of nuclear factor kappa B ligand	0.9999665783200733
52bf1d9e03868f1b06000010	RANKL Ab Denosumab	0.33057989712207814
530f900ee3eabad021000003	generations;Generations	0.08447873828807649
532206819b2d7acc7e00000f	motifs;Motif	0.5819677850484417
517194ef8ed59a060a000011	red blood cells;Erythrocytes;RBC;erythrocytes;erythrocytic;Red Blood Cells;erythrocyte;Erythrocyte;Erythrocytic	0.9965589048594656
51631154298dcd4e5100004e	MULTIPLE MYELOMA;Multiple myeloma;multiple myeloma	0.9999999398215674
533675ced6d3ac6a34000056	form;Form;forms	0.0810839856753191
51bdb644047fa84d1d000001	Major;major	0.22331799459941318
531464a6e3eabad021000014	G>C	0.620397343150421
51595fb0d24251bc0500009c	STAT1;Stat1	0.8596753665242334
51595fb0d24251bc0500009c	CD74	0.6367747608877048
52f8995b2059c6d71c00004a	migraine;MIGRAINE	0.6521427343447809
51387022bee46bd34c000002	Section, NOS;section	0.08488080354438533
532206819b2d7acc7e00000f	immunoaffinity purification	0.622823539988068
51595fb0d24251bc0500009c	beta-catenin;Beta catenin	0.7604760688958203
51595fb0d24251bc0500009c	MUC18	0.8258831081714306
51475d5cd24251bc0500001b	nanometer;Nanometer	0.5854845669754845
517194ef8ed59a060a000011	disease;Disease;diseases;Diseases;condition;conditions	0.5082934525556784
533c3af6c45e13371400000d	MFT	0.9876379669186339
51595fb0d24251bc0500009c	More;more	0.10277340513175369
51631154298dcd4e5100004e	treat;TREAT	0.0862974208552448
5323640b9b2d7acc7e000014	NOTCH3;NOTCH3 gene;notch 3;Notch3 gene;NOTCH3 Gene;Notch homolog 3;Notch3	0.9989134430390882
5323640b9b2d7acc7e000014	Cerebral Autosomal Dominant Arteriopathy;cerebral arteriopathy;Cerebral autosomal dominant arteriopathy;cerebral autosomal dominant arteriopathy	0.9994609689988354
533675ced6d3ac6a34000056	H1R	0.6825464632767063
51631154298dcd4e5100004e	Hitachi General Hospital	0.15113920319226767
513f3d1fbee46bd34c000010	FERROUS SULFATE;ferrous sulphate	0.8297780884271291
513f3d1fbee46bd34c000010	SUCRALFATE;sucralfate	0.739476912967804
513f3d1fbee46bd34c000010	CALCIUM CARBONATE;calcium carbonate	0.8334895233573023
513f3d1fbee46bd34c000010	ALUMINUM CONTAINING ANTACIDS;aluminium-containing antacids	0.6724197217956501
513f3d1fbee46bd34c000010	RALOXIFENE;raloxifene	0.7704087269504816
51595fb0d24251bc0500009c	IDH2	0.8427322300120049
51595fb0d24251bc0500009c	CRABP2	0.8372242572225989
530f900ee3eabad021000003	The hallmarks	0.09251043516592948
51595fb0d24251bc0500009c	SEC14L2	0.8361547940497581
513f3d1fbee46bd34c000010	raloxifene and proton-pump inhibitors	0.45118615711056526
51bdb644047fa84d1d000001	a single transmembrane segment	0.06643724326256939
51475d5cd24251bc0500001b	High-resolution protein structure determination	0.21168948701352264
513f3d1fbee46bd34c000010	CHROMIUM PICOLINATE;chromium picolinate	0.763510975465488
530cefaaad0bf1360c000003	two studies	0.10165934117110315
530cefaaad0bf1360c000003	42%	0.6334982190929029
5312280ce3eabad02100000a	neurofibromatosis type	0.2577800152229531
51475d5cd24251bc0500001b	less than;Less Than	0.10467644723813745
52f8995b2059c6d71c00004a	the frequent restless leg syndrome	0.012124824592520738
530cefaaad0bf1360c000003	no significant difference	0.10397852816287793
533c3af6c45e13371400000d	Multiple Familial Trichoepithelioma;family with multiple familial trichoepithelioma;multiple familial trichoepitheliomas;multiple familial trichoepithelioma	0.9181534862398293
52f8995b2059c6d71c00004a	LRRK2 gene mutation	0.3534979273785408
5323640b9b2d7acc7e000014	stroke and dementia	0.3830034415264229
51595fb0d24251bc0500009c	a selected group;Group A	0.1151225860053144
52bf1d9e03868f1b06000010	quantity;Quantity	0.08542199739240912
51475d5cd24251bc0500001b	Time-resolved protein nanocrystallography	0.22135413511623672
5312280ce3eabad02100000a	the disease and markers	0.04488950349421775
51bdb644047fa84d1d000001	autoantibodies against gp210	0.5374607162863211
514a0a57d24251bc05000051	Flumazenil;FLUMAZENIL;flumazenil	0.9999999995176867
51595fb0d24251bc0500009c	the breast cancer cell lines	0.02351999316803645
514a0a57d24251bc05000051	OD;(OD	0.7346001142715717
515de993298dcd4e51000024	SERTRALINE;sertraline	0.8904953165105702
51631154298dcd4e5100004e	data;Data	0.08573369607509766
515de993298dcd4e51000024	Eighty Nine;Eighty-nine	0.2171285655076925
53124bdae3eabad02100000b	the molecular target;the molecular Target	0.010061263772552257
52f89f4f2059c6d71c00004e	NBEAL2 gene;NBEAL2	0.8402988376547605
530cefaaad0bf1360c000003	use	0.009159616219034465
53124bdae3eabad02100000b	(mTOR;mTOR	0.9938995528899858
5323640b9b2d7acc7e000014	dementing	0.7144451828521308
52bf1d9e03868f1b06000010	) new inhibitors of bone resorption	0.10303311822926496
51475d5cd24251bc0500001b	photo-chemical reaction	0.23541662141177103
5314b20bdae131f847000005	kidney;KIDNEY	0.7166811670716383
514a0a57d24251bc05000051	BZD OD	0.7282086204075044
514a0a57d24251bc05000051	the management	0.23520866956208628
51bdb644047fa84d1d000001	TMEM33	0.8524094855264369
51405cd123fec90375000005	alpha-galactosidase A	0.3972568896888905
5313058de3eabad02100000e	lumbosacral;Lumbosacral vertebrae;lumbo-sacral;lumbosacral transitional vertebrae;Lumbosacral	0.9676055949465703
530cefaaad0bf1360c000003	Campath-1H;Campath 1H;CAMPATH-1H;Campath 1-H;monoclonal antibody CAMPATH-1H;Monoclonal Antibody Campath-1H	0.9998935090423006
5314b20bdae131f847000005	fava beans;Fava Beans	0.1983128328407837
51bdf045047fa84d1d000003	ATG8;Atg8;GABARAPL2;GATE-16	0.9999674146332219
533675ced6d3ac6a34000056	chromosomal;Chromosomal	0.803610036657116
52f89f4f2059c6d71c00004e	a unique combination	0.10216826214139425
51405cd123fec90375000005	the subsequent accumulation in various tissues	0.05623793501309773
514a0a57d24251bc05000051	benzodiazepine-induced sedation	0.7151972877284409
51bdf045047fa84d1d000003	GABARAP;GABA(A) receptor-associated protein	0.9999819588298601
517194ef8ed59a060a000011	Protozoa;Protozoan;protozoan;protozoa	0.8926999459192195
514a0a57d24251bc05000051	overdose;OVERDOSE	0.1883290687439656
532366f09b2d7acc7e000015	cysteine;CYSTEINE	0.9366894360212481
51475d5cd24251bc0500001b	an emerging method with potential	0.101369255739321
51bdf045047fa84d1d000003	addition to ULK1 and ULK2, ATG13 and FIP200	0.1693485450542364
52f89f4f2059c6d71c00004e	GATA1	0.7064036117164993
515993f3d24251bc050000a0	thyronine;-thyronine);Thyronine	0.9235970138408225
515993f3d24251bc050000a0	(T2;T2	0.7849685749623948
515993f3d24251bc050000a0	(3,5-diiodo-L-thyronine);3,5-diiodo-L-thyronine	0.9401967348716169
515993f3d24251bc050000a0	CO23	0.6569340488970437
51bdf045047fa84d1d000003	LC3C;MAP1LC3C	0.8459296548896277
533675ced6d3ac6a34000056	DNA double strand	0.0758846508638302
515993f3d24251bc050000a0	GC-1;GC1	0.9232984075912261
515993f3d24251bc050000a0	DITPA	0.8931799018262592
5313058de3eabad02100000e	a treatment	0.1088149831824355
515993f3d24251bc050000a0	tetrac;tetraiodothyroacetic acid;Tetraiodothyroacetic acid;TETRAC;Tetrac	0.9151488296848388
5141bcd423fec9037500000d	SB225002;SB225002)	0.9118737184636795
52bf1d9e03868f1b06000010	immune responses	0.2140715650134265
533c3af6c45e13371400000d	a heterozygous state	0.1573334535613848
52fa73e82059c6d71c000059	direct methods;direct delivery methods	0.09970456103870425
5313058de3eabad02100000e	causing;Causing	0.08910011283466045
515de993298dcd4e51000024	this pilot study	0.09686493651711922
51631154298dcd4e5100004e	SERUM;serum	0.5865210343495764
530cefaaad0bf1360c000003	MS patients with relapsing	0.050624279013874895
514a0a57d24251bc05000051	A 54-y-old man	0.2285642939187909
533c3af6c45e13371400000d	Brooke-Spiegler syndrome;BROOKE-SPIEGLER SYNDROME	0.9999999690087645
515993f3d24251bc050000a0	KB 2115;KB- 2115	0.681207845029744
515993f3d24251bc050000a0	KB - 141;KB 141	0.544848889578512
53189b05b166e2b80600001e	the lacrimal and/or salivary glands	0.15934013637295458
51bdf045047fa84d1d000003	MAP1LC3B	0.8090945523261666
51bdf045047fa84d1d000003	GABARAP-L1);GABARAPL1;ATG8L	0.999233250566176
52bf1d9e03868f1b06000010	PARICALCITOL;(paricalcitol;paricalcitol	0.4630816230712655
5141bcd423fec9037500000d	G31P	0.605114638807108
530f900ee3eabad021000003	elevated serum 3,3',5-tri-iodothyronine levels	0.3496009887730946
5324a8ac9b2d7acc7e000018	What tyrosine kinase	0.03984359591503826
53189b05b166e2b80600001e	salivary;Salivary	0.7076466921683933
515993f3d24251bc050000a0	T(4)-agarose;T4-agarose	0.8987124618601667
52fa73e82059c6d71c000059	genetic transformation systems	0.08348245200076347
515993f3d24251bc050000a0	3,5-diiodothyropropionic acid	0.561773874912495
53189b05b166e2b80600001e	Dry eye;dry eye	0.20760567390046472
5141bcd423fec9037500000d	SCH-527123;SCH 527123	0.8401490683148212
5324a8ac9b2d7acc7e000018	bcr-abl tyrosine kinase;Bcr-Abl;BCR-ABL Protein Tyrosine Kinase;breakpoint cluster region (BCR) gene;breakpoint cluster region;BCR to ABL;BCR/ABL fusion tyrosine kinase;BCR-ABL protein tyrosine kinase;BCR-ABL fusion protein;tyrosine kinase inhibition of BCR-ABL;BCR-ABL Oncoprotein;BCR ABL Fusion Protein;bcr-abl gene product;BCR-ABL;ABL-BCR;BCR) gene;BCR/ABL;BCR-ABL oncoprotein;bcr-abl oncoprotein;murine leukemia;Bcr-Abl tyrosine kinase;BREAKPOINT CLUSTER REGION;BCR-ABL1 fusion protein;Breakpoint Cluster Region Gene;Bcr-Abl fusion protein;Bcr-Abl Tyrosine Kinase;bcr-abl;BCR-ABL gene;Bcr-Abl protein;product of a chimeric BCR-ABL gene;BCR-ABL tyrosine kinase;BCR-ABL protein;tyrosine kinase activity of Bcr-Abl;BCR-ABL1 Fusion Protein;BCR-ABL transcript with constitutive activation of the BCR-ABL tyrosine kinase;BCR Gene;Bcr-Abl kinase fusion protein;BCR-ABL) tyrosine kinase	1.0
51475d5cd24251bc0500001b	XFELs	0.6745695606656237
514a0a57d24251bc05000051	benzodiazepine agonists without tranquillising or anticonvulsant actions	0.197625069051259
51bdf045047fa84d1d000003	two subfamilies	0.6160200046832479
515993f3d24251bc050000a0	CGS 23425	0.9795386276240342
52fa73e82059c6d71c000059	Mutagenesis, Site-Directed;site-directed plasmid mutagenesis	0.38818636607677104
515993f3d24251bc050000a0	3,5-diidodothyropropionic acid	0.42685504200477253
533c3af6c45e13371400000d	G;g%	0.7298921811465139
530f900ee3eabad021000003	left putamen;Left putamen	0.20220102562696507
515993f3d24251bc050000a0	3-TYROSINE;3-monoiodo-L-tyrosine	0.637031897505338
515993f3d24251bc050000a0	triiodothyroacetic acid;Triiodothyroacetic acid;triac;TRIAC	0.8732957976746961
517194ef8ed59a060a000011	Plasmodium spp.;Plasmodium spp	0.8580764926823098
52bf1d9e03868f1b06000010	nuclear factor-kappaB ligand modulators	0.2074609177380843
515993f3d24251bc050000a0	3,5-T2	0.5844318032763657
52bf1d9e03868f1b06000010	PTH and alkaline phosphatase	0.4396889907483978
515993f3d24251bc050000a0	DIT	0.6495729380991286
5141bcd423fec9037500000d	AZ10397767;AZ10397767)	0.7737426297558451
515993f3d24251bc050000a0	3,5-diiodo-L-tyrosine	0.6197280428830007
515993f3d24251bc050000a0	3,3',5,5'-tetraiodo-thyroacetic acid	0.361681088138341
533c3af6c45e13371400000d	cylindromatosis	0.6891761944227337
53372ba3d6d3ac6a34000058	H3K36 trimethylation	0.7148059950334046
515993f3d24251bc050000a0	(3,3',5-triiodo-D-thyronine)	0.41466300042377047
533c3af6c45e13371400000d	a benign tumour	0.3813099182842793
5141bcd423fec9037500000d	The aim	0.03833831863726741
5313058de3eabad02100000e	characterized;Characterized	0.13384765581364225
515993f3d24251bc050000a0	DIHPA;3,5-diiodo-4-hydroxyphenylpropionic acid	0.8553800883812399
53372ba3d6d3ac6a34000058	estrogen receptor;Estrogen Receptor	0.7658438146570311
5141bcd423fec9037500000d	CXCR1	0.8447650120029087
517194ef8ed59a060a000011	the efficient synthesis	0.0789690144435673
5141bcd423fec9037500000d	SCH-479833;SCH 479833	0.6328857889178788
51bdf045047fa84d1d000003	MAP1LC3A;LC3	0.9539396765499604
515de993298dcd4e51000024	ICBT	0.6541310156190538
51bdf045047fa84d1d000003	elongation	0.6540857616001267
5141bcd423fec9037500000d	malignant cell apoptosis	0.4640613769302878
52fa73e82059c6d71c000059	Bacterial artificial chromosomes (BACs	0.414567451585183
52bf1d9e03868f1b06000010	cancers	0.10693110642703418
515993f3d24251bc050000a0	The relative binding affinity	0.2652212170157054
514241fcd24251bc05000006	PSP1;paraspeckle protein component 1;PSPC1;paraspeckle component 1;PARASPECKLE COMPONENT 1	0.993060833312153
515993f3d24251bc050000a0	D-T3	0.6374277508531891
5149a61ed24251bc05000044	detect	0.10880645062126032
517194ef8ed59a060a000011	Plasmodium species;species of the parasitic protozoan genus Plasmodium;Plasmodium sp	0.8430571634268714
5149a61ed24251bc05000044	BETAWARE	0.6503104059076618
515993f3d24251bc050000a0	3,5-Dimethyl-3'-isopropyl-L-thyronine	0.4742272244597728
515de993298dcd4e51000024	child anxiety/depression	0.05995733538370279
515993f3d24251bc050000a0	DIMIT	0.7116591740735579
515993f3d24251bc050000a0	3,5-diiodo-3'-isopropylthyroacetic acid	0.4815157428178611
515993f3d24251bc050000a0	IpTA2	0.696504356352969
530cefaaad0bf1360c000003	early multiple sclerosis	0.030733768885963273
514a0a57d24251bc05000051	17 double-blind	0.22284949850605915
51631154298dcd4e5100004e	efficient;Efficient	0.11018897728564213
52c7275103868f1b0600001c	Autosomal dominant;autosomal dominant inheritance;Autosomal Dominant Inheritance;autosomal dominant	0.9794434971506575
52c7275103868f1b0600001c	FGFR2 gene;FGFR2 Gene	0.4164454518802119
515de993298dcd4e51000024	conflict management for couples	0.04795426003138172
514a0a57d24251bc05000051	14 placebo patients (p	0.5381349917908809
514241fcd24251bc05000006	SFPQ	0.8815188950602274
52c7275103868f1b0600001c	Severe syndactyly;severe syndactyly	0.1906360199632044
53372ba3d6d3ac6a34000058	Recent studies	0.09938111083170924
514241fcd24251bc05000006	found;Found	0.08698469964731581
5324a8ac9b2d7acc7e000018	ALL)	0.13116993088138468
5324a8ac9b2d7acc7e000018	ABL-kinase inhibitors;Abl kinase inhibitors	0.8111695528193481
517194ef8ed59a060a000011	a standard procedure in many systems	0.07651283090310838
51bdf045047fa84d1d000003	microtubule-associated protein-1 light chain 3A	0.2564238193978203
51631154298dcd4e5100004e	BZM	0.7140273380815271
533c3af6c45e13371400000d	Epidermal;epidermal	0.590491393349618
514241fcd24251bc05000006	an RNA-dependent manner	0.2681954564731772
52fb42752059c6d71c00005e	tetrac	0.6721283437940924
52c7275103868f1b0600001c	Early;early	0.10050142317701974
530f900ee3eabad021000003	a thyroid hormone transporter	0.17433526097802304
515deafd298dcd4e51000025	ACHALASIA;Esophageal Achalasia;achalasia;esophageal achalasia	0.8202608218601158
533c3af6c45e13371400000d	the expression of angiogenic factors	0.06191919073849469
517194ef8ed59a060a000011	defense;Defense	0.08869581446227415
514241fcd24251bc05000006	right handed;right-handed	0.19773784446388512
515a7ffdd24251bc050000a5	phosphorylation of c-Jun;JUN phosphorylation	0.4415160706996204
514241fcd24251bc05000006	Human;human	0.09656639768475102
517194ef8ed59a060a000011	's main line	0.155241794720975
515a7ffdd24251bc050000a5	transactivation of the c-Jun promoter	0.26401223471635377
53372ba3d6d3ac6a34000058	Active;active	0.08116945155479985
5148691bd24251bc0500002d	Neuroprotective Effect;neuroprotective effect	0.20081035150493634
52fb42752059c6d71c00005e	natural;Natural	0.07202904494506485
5148691bd24251bc0500002d	JNK	0.9943266607961155
52fb42752059c6d71c00005e	hormone analog;hormone analogue	0.12724626601135983
5319abe4b166e2b80600002e	N-cadherin	0.7358705059052667
51631154298dcd4e5100004e	CETUXIMAB;cetuximab	0.6712694831146656
5318367cb166e2b806000012	parkin gene;PARK2;AR-JP;Parkin gene;parkin;PARKIN;Parkin	0.9997504353295464
5319abe4b166e2b80600002e	N-cadherin by a transcription-independent mechanism	0.13581073370680458
52c7275103868f1b0600001c	equal;Equal	0.08529655562821958
52fb42752059c6d71c00005e	TRIAC	0.8747048207768937
515a7ffdd24251bc050000a5	Approach;approach	0.07772007808732126
53398855d6d3ac6a3400005b	readers;reader;READER	0.09172436169114744
533c3af6c45e13371400000d	BSS	0.7088580171235523
5318367cb166e2b806000012	DJ-1;PARK7	0.9994844993999287
515a7ffdd24251bc050000a5	intracellular	0.6550363867763138
5318367cb166e2b806000012	PINK1) gene;PINK1;PINK-1	0.9964819514189034
531375a6e3eabad021000011	NON-SUSTAINED VENTRICULAR TACHYCARDIA;Non-Sustained VT;Nonsustained ventricular tachycardia;nonsustained ventricular tachycardia;non-sustained ventricular tachycardia;Nonsustained VT	0.9979641790254141
53398855d6d3ac6a3400005b	acetylated lysines	0.9252377747254039
51631154298dcd4e5100004e	Bortezomib determined dose-dependent growth inhibition in a nine cancer cell line panel	0.02005075759078515
52c7275103868f1b0600001c	This report	0.17135057240175797
530cefaaad0bf1360c000007	Ponezumab;PONEZUMAB	0.8290853055867146
52c7311903868f1b0600001d	one;ONE	0.1200557586341947
5318367cb166e2b806000012	ATP13A2	0.9647427785386872
5318367cb166e2b806000012	PARK9	0.8010355593735025
5318367cb166e2b806000012	PARK14;PLA2G6	0.8415819110212767
530cefaaad0bf1360c000007	bapineuzumab;BAPINEUZUMAB;Bapineuzumab	0.972394925784712
5318367cb166e2b806000012	PARK15	0.8290848910476858
5324a8ac9b2d7acc7e000018	mediated	0.6461742303355847
5149a61ed24251bc05000044	shows;shown;show;Show	0.17051021365172614
533c3af6c45e13371400000d	2 large families	0.15602765466680596
52fb78d82059c6d71c000068	I137M	0.7268960116647094
5318367cb166e2b806000012	FBX07	0.6559406375964753
514a0a57d24251bc05000051	Study;study	0.0806888143107879
5318367cb166e2b806000012	PARK6	0.8164770289948147
511a20f3df1ebcce7d00000c	Psoriasis;psoriasis;PSORIASIS	0.8084612504793622
511a20f3df1ebcce7d00000c	alopecia;ALOPECIA	0.6388933457326608
530cefaaad0bf1360c000007	solanezumab;SOLANEZUMAB;Solanezumab	0.9622426662039159
52fb78d82059c6d71c000068	Sequencing;sequencing	0.6782994671908474
5149a61ed24251bc05000044	BOCTOPUS	0.6178277383287735
511a20f3df1ebcce7d00000c	Class;class	0.07954816456645407
531375a6e3eabad021000011	The appearance;the appearance	0.04324660531677041
53398855d6d3ac6a3400005b	Containing;containing	0.08607385279954335
511a20f3df1ebcce7d00000c	ARTHRITIS, PSORIATIC;psoriatic arthritis	0.8013926516512738
52fb78d82059c6d71c000068	V728I	0.6517738421776742
52fb78d82059c6d71c000068	N1443S	0.6521403033434002
52fb78d82059c6d71c000068	E1152X	0.6481145734712915
530cefaaad0bf1360c000007	with;Addition;addition;With	0.09259864240532843
5149a61ed24251bc05000044	TMBHMM	0.8301490010425882
52fb78d82059c6d71c000068	(R27H	0.6194620297525363
52fb78d82059c6d71c000068	G1743R (	0.6365745806911213
511a20f3df1ebcce7d00000c	liver toxicity;Hepatic toxicity	0.43246367120087914
5318367cb166e2b806000012	PINK-1 for an autosomal-recessive early-onset variant	0.17774918782310165
53398855d6d3ac6a3400005b	Histone H4;histone H4	0.498748451187532
5319abe4b166e2b80600002e	histone H3 on lysine 9 (H3K9me2)	0.6224366480530432
531375a6e3eabad021000011	sustained ventricular tachycardia;SUSTAINED VENTRICULAR TACHYCARDIA	0.5626330351457003
514a0a57d24251bc05000051	terminated	0.6409753325799863
52df8ce798d023950500000d	QUERCETIN;Quercetin;quercetin	0.8453121111405655
52fb78d82059c6d71c000068	electrocardiograph;electrocardiographic	0.5882286973308188
511a20f3df1ebcce7d00000c	Leucopoenia;LEUCOPENIA;Leukopenia	0.8347808511953534
5148885ad24251bc05000032	VKORC1;VKORC1 gene;VKORC1 Gene;VKORC1 genes	0.9999998206409713
52df8ce798d023950500000d	PERCENT;percent	0.5884375203516621
530cefaaad0bf1360c000007	a putative disease-modifying treatment	0.06831872878992874
5148885ad24251bc05000032	CYP2C9;CYP) 2C9;. CYP2C9	0.9983069659837086
515b30d8d24251bc050000b0	lacrimal gland;LACRIMAL GLAND	0.9051871559484602
515deafd298dcd4e51000025	4 5;4.5	0.6090662588886405
52df8ce798d023950500000d	vitamin C;Vitamins C;VITAMIN C	0.8345801581032561
5319abe4b166e2b80600002e	Zeb1;ZEB1	0.9203006280012415
5324a8ac9b2d7acc7e000018	a specific small molecule inhibitor	0.05956770680589339
51631154298dcd4e5100004e	0;0%	0.6312302377821145
5148885ad24251bc05000032	ORM1 gene;ORM1;ORM1 as another polymorphic gene	0.8984181710077487
5318380bb166e2b806000013	HSP90	0.811258218661278
5318380bb166e2b806000013	CDC37);CDC37	0.7705176336682887
5149a61ed24251bc05000044	BTMX	0.6568841967739896
5149a61ed24251bc05000044	the protein structure) of transmembrane residues	0.07168089235573882
511a20f3df1ebcce7d00000c	Elevated transaminases;elevated transaminases	0.572298443865107
5318380bb166e2b806000013	(GRP75;GRP75	0.8118934864694644
5318380bb166e2b806000013	HSP60	0.7135370572464048
5318380bb166e2b806000013	LRPPRC	0.713222413277753
5149a61ed24251bc05000044	beta-barrel proteins	0.1807299572943098
5318380bb166e2b806000013	TUFM);TUFM	0.728581975685598
533be71dfd9a95ea0d000009	lysine 4 of histone H3;Histone H3 Lysine 4;histone H3 at lysine 4;H3 K4;H3K4;of lysine 4 of histone H3;Lysine 4 of Histone H3;Histone H3 Lys4;histone H3 lysine 4;H3K4);Lys4 of histone H3	0.9998584699286169
530cefaaad0bf1360c000007	some dose dependent adverse events during the Phase II portion	0.0557339266764836
515b30d8d24251bc050000b0	Thyroid, NOS;thyroid	0.6596615196620139
515deafd298dcd4e51000025	60 (30%) affected children	0.1249287364463448
531375a6e3eabad021000011	Family History of Sudden Cardiac Death;family history of sudden cardiac death	0.004814344615110402
5318380bb166e2b806000013	binds;Bind	0.07988989061768259
5318380bb166e2b806000013	PICK1	0.8667943574824596
5343bdd6aeec6fbd07000001	Region;region	0.1434227138352826
52df8ce798d023950500000d	1 SD of peak speed	0.16193807895758097
51631154298dcd4e5100004e	vitro and	0.27335029959357726
5343bdd6aeec6fbd07000001	serine 5;serine-5	0.8505683377190288
51631154298dcd4e5100004e	liposomal doxorubicin (PegLD)	0.40974489830479
5319abe4b166e2b80600002e	Twist;twist	0.09210858798831921
517194ef8ed59a060a000011	Few	0.11089340859743592
5318380bb166e2b806000013	XAPC7;PSMA7	0.6502066468986921
5149a61ed24251bc05000044	A new genetic algorithm (GA)	0.22560865255618215
5148885ad24251bc05000032	dosage;dosages;Dosage;Dosages;dose;DOSE	0.8175241742106876
5149a61ed24251bc05000044	HHomp	0.7356477133090864
5148885ad24251bc05000032	CYP4F2;CYP4F2 gene	0.9846495526325717
515b30d8d24251bc050000b0	with;With	0.08323255922554533
530cefaaad0bf1360c000007	the potential treatment of Alzheimer disease (AD)	0.023619888668633862
515deafd298dcd4e51000025	ESOPHAGITIS, REFLUX;reflux esophagitis	0.8319350202793491
515deafd298dcd4e51000025	Chronic Gastritis;chronic gastritis	0.3983330183286498
5318380bb166e2b806000013	Pael receptor	0.7487371863853237
515deafd298dcd4e51000025	Chronic duodenitis;chronic duodenitis	0.4253671233037448
52fb78d82059c6d71c000068	E1784K (14x)	0.6288668470550464
52fb78d82059c6d71c000068	F861WfsX90 (11x)	0.630143331991822
5149a61ed24251bc05000044	BOMP	0.8966930366303083
52fb78d82059c6d71c000068	D356N (8x)	0.62441003977311
52fb78d82059c6d71c000068	G1408R (7x)	0.6197994967096765
530cefaaad0bf1360c000007	the anti-AÎ² monoclonal antibody bapineuzumab	0.2461155145692404
511a20f3df1ebcce7d00000c	Pancreatitis;PANCREATITIS	0.7686880142766909
515b30d8d24251bc050000b0	Lacrimal fluid;tear fluid	0.18877728180319073
52fb78d82059c6d71c000068	G400A	0.7278165975394002
53188992b166e2b806000019	c-kit;c kit	0.5526782563430127
533be71dfd9a95ea0d000009	Family;family	0.07840294966121779
5324a8ac9b2d7acc7e000018	a reciprocal translocation between chromosome 9 and 22	0.15428308243638872
52df8ce798d023950500000d	MELATONIN;melatonin	0.7448483099235209
53188992b166e2b806000019	platelet-derived growth factor receptor (PDGFR);platelet-derived growth factor receptor (PDGFR	0.686509729781869
5149a61ed24251bc05000044	TMB-Hunt	0.746378443156512
5324a8ac9b2d7acc7e000018	the peripheral blood of patients	0.039214371662945766
5149a61ed24251bc05000044	transFold;TransFold	0.7378188929281546
530cefaaad0bf1360c000007	a single dose	0.09986889488312437
511a20f3df1ebcce7d00000c	Pericarditis;PERICARDITIS	0.7824902264743289
52fb78d82059c6d71c000068	W822X	0.6742933757490723
51631154298dcd4e5100004e	approved;Approved	0.08533656663701708
53188992b166e2b806000019	BCR/ABL;BCR-ABL	0.8676602259826518
515deafd298dcd4e51000025	the autistic children	0.02021077172910436
533be71dfd9a95ea0d000009	a mammalian homolog of Drosophila trithorax	0.3152152700476134
5319abe4b166e2b80600002e	and;And	0.09770893267185375
511a20f3df1ebcce7d00000c	PARESTHESIAS;paresthesias;paresthesia;PARAESTHESIA	0.5763655519601942
52fb78d82059c6d71c000068	Q55X	0.7456362035186962
5324a8ac9b2d7acc7e000018	a major breakthrough	0.13406406970408402
511a20f3df1ebcce7d00000c	Mean;mean	0.08666325866320075
5149a61ed24251bc05000044	ProfTMB;PROFtmb	0.6497412099651672
5314a7a4dae131f847000003	L29Q	0.743328628200161
533be71dfd9a95ea0d000009	Order;order	0.09044646886319406
52fb78d82059c6d71c000068	V95I	0.676953772738013
52fb78d82059c6d71c000068	A1649V	0.6819846712882437
52fb78d82059c6d71c000068	delF1617	0.6813795986293388
515d7693298dcd4e5100000c	Keratins;Keratin;keratin;keratins	0.5162063284391197
51635202298dcd4e5100004f	Autosomal dominant;Autosomal Dominant Inheritance;autosomal dominant pattern of inheritance;autosomal dominant;autosomal dominant inheritance	0.817737921698626
5314a7a4dae131f847000003	calcium binding;Calcium Binding	0.7686696595653622
5343caffaeec6fbd07000002	Human;human	0.012794567453498015
511a20f3df1ebcce7d00000c	Hemolysis;HAEMOLYSIS;hemolysis	0.6721164706845266
5314a7a4dae131f847000003	open;Open	0.09395994033318136
531d6bfc267d7dd053000007	mouse lethality assay;mouse bioassay;mouse assay;Mouse bioassay	0.6195241919482293
5343caffaeec6fbd07000002	Residue;residues;residue	0.09597463045922569
5314a7a4dae131f847000003	domain;Domain	0.12770666275040413
5319abe4b166e2b80600002e	SIP1;SIP-1	0.8965389721165086
5319abe4b166e2b80600002e	DELTAEF1;deltaEF1	0.9986132741241267
5343caffaeec6fbd07000002	SeP);Sepp1);SEPP1;selenoprotein P;selenoprotein-P;Selenoprotein P;Sepp1;SeP	0.9908349533951486
530cefaaad0bf1360c00000c	Nelarabine;NELARABINE;nelarabine	0.7652482025375679
5343caffaeec6fbd07000002	to;TO	0.09744011020034853
517194ef8ed59a060a000011	the principal causative agent	0.016264253000791446
51635202298dcd4e5100004f	2 (DM2)	0.49209469459423727
531d6bfc267d7dd053000007	Bioassay;bioassay;assays;Assay;assay	0.8817650969057568
51635202298dcd4e5100004f	the zinc finger protein	0.10830331719056749
5156be17d24251bc05000086	VENLAFAXINE HYDROCHLORIDE;venlafaxine hydrochloride	0.7900139402690217
517194ef8ed59a060a000011	this parasitic disease	0.20265707033595004
5149a61ed24251bc05000044	TMBETAPRED-RBF	0.5381736624606982
5148885ad24251bc05000032	sensitivity to coumarins	0.07817492130888552
512d0e635274a5fb07000005	etanercept;Etanercept;ETANERCEPT	0.9293353099155316
5314a7a4dae131f847000003	A8V	0.877266861235775
5314a7a4dae131f847000003	the structural effects	0.09177906308622232
531d6bfc267d7dd053000007	differentiated cell models	0.14699860349357513
52df8ce798d023950500000d	epigallocatechin gallate;EPIGALLOCATECHIN GALLATE	0.724494112957902
515df86a298dcd4e5100002e	Disease, Graves;Graves' disease	0.9320092042655799
530cefaaad0bf1360c00000c	PENTOSTATIN;DCF;deoxycoformycin;Pentostatin;2'-Deoxycoformycin;2'-deoxycoformycin;pentostatin;Deoxycoformycin;DCF)	0.7566750464630917
52fb78d82059c6d71c000068	K1527R	0.6951155585541217
52fb78d82059c6d71c000068	A1569P);A1569P	0.6985040069699643
5319abe4b166e2b80600002e	transcriptional repression of E-cadherin	0.19452689239077192
52df8ce798d023950500000d	L 502;L. paracasei IMC 502	0.6058336976142576
512d0e635274a5fb07000005	a higher risk than etanercept (ETA	0.19244322663557226
5314a7a4dae131f847000003	A31S	0.6513676197866067
52fb78d82059c6d71c000068	the gene	0.07763166932568631
5156be17d24251bc05000086	HT2A	0.6569340488970437
5148885ad24251bc05000032	EPHX1	0.9170900531004512
52fb78d82059c6d71c000068	R367H	0.7551269072200443
515df86a298dcd4e5100002e	breast cancer;-- Breast Cancer	0.8236496390476684
515df86a298dcd4e5100002e	amphiphysin;Amphiphysin	0.7845179916525132
52df8ce798d023950500000d	Rhodiola Rosea;Rhodiola rosea	0.6743726596579337
52fb78d82059c6d71c000068	A735V	0.6868226107373065
515df199298dcd4e5100002a	"liberation therapy	0.47493672273585946
5149a61ed24251bc05000044	TMBpro	0.7030364770025642
531d6bfc267d7dd053000007	peptide cleavage assay	0.7182664836250907
52fb78d82059c6d71c000068	R1192Q	0.6823853995252973
5314a7a4dae131f847000003	E134D	0.9296528615286321
5343fc1aaeec6fbd07000003	Neurofibromatosis Type 1;neurofibromatosis type I;neurofibromatosis;neurofibromatosis 1;NF1 );Neurofibromatosis;Neurofibromatosis 1;type 1 neurofibromatosis;Nf1;Neurofibromatosis 1 gene;NF1 Gene;NF1;NF-1;NF1 gene;Neurofibromatosis 1 Gene;Neurofibromatosis, Type 1;neurofibromatosis type 1 (NF1);neurofibromatosis type 1 (NF1) gene;Neurofibromatosis type 1;neurofibromatosis type 1 gene;NF1);neurofibromatosis type 1	0.9999999999999996
5148885ad24251bc05000032	CYP2C18	0.8701057185876523
5148885ad24251bc05000032	CYP2C19	0.8597793110539919
52df8ce798d023950500000d	vitamin E;VITAMIN E	0.40290462663131216
515df86a298dcd4e5100002e	IDDM);insulin-dependent diabetes mellitus;IDDM;DIABETES MELLITUS, INSULIN DEPENDENT;insulin-dependent) diabetes mellitus	0.9999891335624093
5148885ad24251bc05000032	CYP3A5	0.8516225808642636
5148885ad24251bc05000032	PROTEIN;protein;Protein S;protein S	0.4190822698186268
5148885ad24251bc05000032	clotting factor V;clotting factor v;factor V	0.5612309338391858
533c2230c45e133714000002	monomers	0.6470225669911658
52df8ce798d023950500000d	zinc;ZINC	0.7445158584399478
52fb78d82059c6d71c000068	D1795	0.6648539156317598
512d2fff5274a5fb07000006	transcriptional initiation	0.19636457145893899
5343fc1aaeec6fbd07000003	NF1 tumor-suppressor gene	0.1823470907942731
51651e24298dcd4e51000054	three;Three	0.8000832222059223
5343fc1aaeec6fbd07000003	haploinsufficiency of the NF1 tumor-suppressor gene	0.11274274724098735
5131fa145274a5fb07000009	the main causes	0.0030170357073466057
5343fc1aaeec6fbd07000003	a common disorder	0.12890037233404875
5300aad02059c6d71c000080	the U.S. experience	0.14027239044913917
5131fa145274a5fb07000009	cystic fibrosis;CF;CYSTIC FIBROSIS	0.9999960684930674
5300aad02059c6d71c000080	football;Football	0.08371346962157798
51651e24298dcd4e51000054	moieties at position 1	0.22128945888393467
5319abffb166e2b80600002f	cytokine;Cytokines;Cytokine;cytokines	0.9793839442482303
5300aad02059c6d71c000080	soccer;Soccer	0.10493650758516924
5300aad02059c6d71c000080	Cricket;cricket	0.5892388340853222
5300aad02059c6d71c000080	hockey;Hockey	0.10727980944089616
5314a7a4dae131f847000003	One mutant	0.2511100760734934
5156be17d24251bc05000086	Major Depression;major depression	0.23494370153642027
51656c94298dcd4e51000058	X-linked recessive inheritance;X-linked;X-linked inheritance;X linked;X-LINKED;X-Linked Inheritance	0.999960342984211
5314a7a4dae131f847000003	A23Q)	0.635239814541552
515df86a298dcd4e5100002e	led;LED	0.1001746050181285
51656c94298dcd4e51000058	Autosomal dominant;autosomal dominant inheritance;Autosomal Dominant Inheritance;autosomal dominant	0.9970751923597461
5300aad02059c6d71c000080	Baseball;baseball	0.20885801821208477
5319abffb166e2b80600002f	FGFR1-4	0.6556624222151748
5314a7a4dae131f847000003	D145E;D145E)	0.8586936994536122
515df86a298dcd4e5100002e	128	0.6561830520590722
5131fa145274a5fb07000009	three;Three	0.08418656771815339
533c2230c45e133714000002	immunity	0.6052233589402937
5131fa145274a5fb07000009	cystic fibrosis (CF);cystic fibrosis (CF	0.8785530320522127
530cefaaad0bf1360c00000d	Transition;transitions	0.08305314085242181
533c2230c45e133714000002	100;100%	0.5814588513991423
531d6bfc267d7dd053000007	Toxin;toxin	0.7252875111082582
515df86a298dcd4e5100002e	Antigen;antigen	0.5879792890371432
5131fa145274a5fb07000009	aneuploidy, CMV, CF and fetal growth restriction	0.2521015943109673
5319abffb166e2b80600002f	PD173074 suppressed cellular proliferation	0.6085771501383573
5148885ad24251bc05000032	Medicated;medicated	0.5886058882124273
5314a7a4dae131f847000003	C84Y	0.6561899663107194
52e0141498d023950500000e	activity of specific;Specific Activity	0.03809477041653574
5314a7a4dae131f847000003	the last 10 years	0.11124355184529207
5343fc1aaeec6fbd07000003	nevoid basal cell carcinoma (Gorlin) syndromes	0.35756522275573155
52e0141498d023950500000e	a significant growth rate deficit	0.07887791285934051
5131fa145274a5fb07000009	CMV infection;cytomegalovirus (CMV) infection;CYTOMEGALOVIRUS INFECTION;CMV INFECTION	0.7341346674180581
515df86a298dcd4e5100002e	Support, NOS;support	0.10252431477713404
5300aad02059c6d71c000080	Lacrosse;lacrosse	0.5864540852618065
53215fca9b2d7acc7e000005	MIB	0.8312874667095429
533c2230c45e133714000002	binding of the PRY-SPRY domain	0.055247244243445626
517194ef8ed59a060a000011	the genome from P. falciparum	0.23156061476124948
5131fa145274a5fb07000009	32.2%	0.6658980999140568
53215fca9b2d7acc7e000005	MINOS;Mino;MINOS)	0.9881725998048072
515df86a298dcd4e5100002e	dementia	0.8662294153110096
5324a8ac9b2d7acc7e000018	stem cell factor;Stem Cell Factor	0.1426014317028995
5319abffb166e2b80600002f	TGF-Î²2	0.9343098576914356
533c2230c45e133714000002	neural differentiation	0.7272294124086284
51656c94298dcd4e51000058	electrical atriomyopathy in the absence	0.06867532682436633
5149a61ed24251bc05000044	abundance;Abundance	0.5891424124015227
533c2230c45e133714000002	degradation of 80K-H	0.4294375315264028
515df199298dcd4e5100002a	the venous stenoses	0.13221471339423113
530cefaaad0bf1360c00000d	an amplified peak release	0.25875257890638104
515df86a298dcd4e5100002e	clinical and electromyographic features	0.25367013402466965
52e0141498d023950500000e	impaired seedling establishment	0.34557851708859816
5343fc1aaeec6fbd07000003	Term;termed	0.11913578700420041
5156be17d24251bc05000086	depression treatment	0.2580934891490023
53215fca9b2d7acc7e000005	mitochondrial inner membrane organizing system	0.5516150115690717
533c2230c45e133714000002	embryonic development;Embryonic Development	0.38577451453350303
530cefaaad0bf1360c00000d	curves;Curve	0.08381380458261978
515ffc2b298dcd4e51000035	Aspergillus terreus	0.9999985297788148
5131fa145274a5fb07000009	the early and only sign	0.05690725826509267
5149a61ed24251bc05000044	Entire;entire	0.07098999286140813
531b1e3cb166e2b80600003b	H3K27me3	0.8583733388099489
52e0141498d023950500000e	lon1 mutants	0.7095748559002389
515ffc2b298dcd4e51000035	LOVASTATIN;lovastatin	0.8297561017378139
517194ef8ed59a060a000011	dependent protein kinases	0.14888087622164584
5319abffb166e2b80600002f	TNF-Î±	0.7958238461335266
53215fca9b2d7acc7e000005	SAM	0.8652335475564391
515df199298dcd4e5100002a	Jugular Vein;jugular vein	0.8838810179534001
530cefaaad0bf1360c00000d	Facies;facies	0.558451694597766
533c2230c45e133714000002	immune defence	0.5510553852901451
5306158358348c0f52000001	a complex genetic disease	0.08327242590285526
517194ef8ed59a060a000011	the vast majority of the 300â€“500 million episodes	0.02716905671707318
515ffc2b298dcd4e51000035	a parent strain for lovastatin production)	0.03872833458868662
5324a8ac9b2d7acc7e000018	significant activity	0.0953927409688912
5131fa145274a5fb07000009	fetal aneuploidy	0.49492563662079786
531b1e3cb166e2b80600003b	H3K36me	0.6496712823129352
530cefaaad0bf1360c00000d	thyroid gland;THYROID GLAND;Thyroid, NOS;thyroid;Thyroid	0.9761470638465559
517194ef8ed59a060a000011	the vector	0.12309658816715778
5344155faeec6fbd07000005	the inheritance pattern	0.005187814342155911
5319abffb166e2b80600002f	Notch1);notch 1;Notch1;Notch-1	0.7181477665225099
52e203bc98d0239505000011	Frequency;frequency	0.09186611137996571
5156be75d24251bc05000088	In Vivo;in vivo	0.1808852010805276
5324a8ac9b2d7acc7e000018	571)	0.3872643775667449
515ffc2b298dcd4e51000035	biotechnological processes	0.051899863132053636
5156be75d24251bc05000088	Chronic lymphocytic leukemia (CLL)	0.3145870128004492
5344155faeec6fbd07000005	X-linked recessive;X- linked recessive	0.8770755249145217
5324bdba9b2d7acc7e00001a	ultrasonography;Diagnostic Ultrasound;ultrasound;ultrasound (US) techniques;ULTRASOUND;Ultrasonography;ultrasound techniques	0.9839367216482252
515ffc2b298dcd4e51000035	Aspergillus niger	0.90859181701378
5306158358348c0f52000001	defect;Defect	0.11315186382731224
5324a8ac9b2d7acc7e000018	FORMERLY;formerly	0.07299363163584992
5149a61ed24251bc05000044	HMM-B2TMR	0.6184998614329666
52e203bc98d0239505000011	TA;Ta	0.6294116606821202
5149a61ed24251bc05000044	PRED-TMBB	0.9292369203144096
52e203bc98d0239505000011	CG	0.7196510122497088
5319abffb166e2b80600002f	GF-Î²	0.785896733748707
515df199298dcd4e5100002a	long-term effects;Long-Term Effects	0.05095151462939632
531b1e3cb166e2b80600003b	H3K27	0.6551508403784178
5319abffb166e2b80600002f	immune;Immune	0.1073516200164666
5156be75d24251bc05000088	3p	0.7665255001323724
5131fa145274a5fb07000009	vaginal bleeding;VAGINAL BLEEDING	0.7949936202209956
5344155faeec6fbd07000005	long arm	0.10095483410505811
530cefaaad0bf1360c00000d	primary neonatal thyroid screening	0.2225726143505903
532c0d7fd6d3ac6a3400001c	used in effective alignment of;using;Using;Use of	0.9179479068470624
533c384dc45e133714000006	genomic positions	0.018357896834595062
5319abffb166e2b80600002f	metastatic;Metastatic	0.6087479444294992
532c0d7fd6d3ac6a3400001c	LigandScout program	0.0997648076152843
5319abffb166e2b80600002f	Wnt	0.6833047881506987
5324bdba9b2d7acc7e00001a	to;TO;To	0.14504554099495895
5306158358348c0f52000001	deletions;Deletions	0.7531093993696187
51656c94298dcd4e51000058	Autosomal Recessive Inheritance;Autosomal recessive;autosomal recessive inheritance;autosomal recessive	0.665324463428358
515ffc2b298dcd4e51000035	free	0.10879662007094759
515ffc2b298dcd4e51000035	Media;media	0.12624185878686656
532c0d7fd6d3ac6a3400001c	Discovery Studio program	0.06251083750752542
5306158358348c0f52000001	15q11-13 deletions of paternal origin	0.2875310009177638
5131fa145274a5fb07000009	known;Known	0.09626510658019462
5156be75d24251bc05000088	Osteosarcoma;OSTEOSARCOMA;osteosarcoma	0.8748049482082189
532c0d7fd6d3ac6a3400001c	Screening;screening	0.06623356553693874
5148885ad24251bc05000032	PROC	0.7997557056603496
532c0d7fd6d3ac6a3400001c	catalyst;CATALYST;Catalyst	0.9728719238347625
5148885ad24251bc05000032	GGCX	0.8231555659314397
533c384dc45e133714000006	mouse liver;Mouse Liver	0.07998208659744376
51656c94298dcd4e51000058	the STA gene on locus Xq2	0.2128895127018237
5319abffb166e2b80600002f	-induced EMT	0.6258604458323453
5306158358348c0f52000001	rare imprinting mutations	0.3473968361091016
515df199298dcd4e5100002a	patients (261 women	0.15595036789136438
533c384dc45e133714000006	inactive X chromosome	0.9024217597846765
515ffc2b298dcd4e51000035	Cloning of the cadA gene;Gene Cloning	0.136391016526919
5156be75d24251bc05000088	Mild Cognitive Impairment;Cognitive impairment, mild	0.10301512642075784
5306158358348c0f52000001	efficient;Efficient	0.09588505223139962
532c0d7fd6d3ac6a3400001c	different;Different	0.07421632395360638
52e8e93498d023950500001e	the mode	0.0033926788535171607
52e8e93498d023950500001e	Autosomal dominant;autosomal dominant	0.3690028948380841
531b3ff3b166e2b80600003d	Par6;PAR6	0.9076308935868953
532c0d7fd6d3ac6a3400001c	PharmaGist	0.6788126441721624
515ffc2b298dcd4e51000035	Ustilago maydis;USTILAGO MAYDIS	0.5777766721389745
5139b31dbee46bd34c000004	Experimental Autoimmune Encephalomyelitis (EAE);Experimental autoimmune encephalomyelitis (EAE);experimental autoimmune encephalomyelitis (EAE);experimental autoimmune encephalomyelitis (EAE	0.9999777605089086
534ab91eaeec6fbd07000012	absence of hepaCAM gene expression	0.09698240563456605
531b3ff3b166e2b80600003d	aPKC	0.8359149840901482
534ab91eaeec6fbd07000012	APC	0.9617262457544392
5149a61ed24251bc05000044	TBBPred	0.624885911066404
52e929eb98d0239505000023	TIME;time	0.0844815097401118
5149a61ed24251bc05000044	the prediction and discrimination	0.015334708549500963
5156be75d24251bc05000088	epilepsy;EPILEPSY	0.8361380572993751
5319abffb166e2b80600002f	EGF	0.6867928740864357
5319abffb166e2b80600002f	bFGF	0.6822601169899725
52e929eb98d0239505000023	MECP1 COMPLEX;MeCP1 complex	0.3936203199958702
52e929eb98d0239505000023	ACF/WCRF complex;ACF complex	0.5306622905932737
5156be75d24251bc05000088	Profiling;profiles;Profile	0.4897706801076577
534ab91eaeec6fbd07000012	showed;Show	0.12094879077320134
5148885ad24251bc05000032	variant CYP2C9 alleles	0.7909289379143853
52e929eb98d0239505000023	Gfi-1b	0.6545195262665254
534ab91eaeec6fbd07000012	RARÎ²(2)	0.7349972552973844
52e929eb98d0239505000023	FOG-1	0.6511080031032365
52e929eb98d0239505000023	TAL-1	0.725793182542225
5319abffb166e2b80600002f	Shape;shape	0.10452542513765425
5324bdba9b2d7acc7e00001a	female;FEMALE	0.08278232937824838
52e929eb98d0239505000023	LMO2-C	0.7381210095717843
51600ab3298dcd4e51000036	frontotemporal dementia (FTD	0.8349570650502377
5156be75d24251bc05000088	the later occurrence of spontaneous seizures	0.2827142006878821
52e929eb98d0239505000023	LDB-1;Ldb-1	0.8260469039853138
514a0f4ad24251bc05000053	70 genes	0.440325346549948
532c0d7fd6d3ac6a3400001c	HypoGen module	0.7268224650761306
531b3ff3b166e2b80600003d	SIRT1	0.9786420753920834
531b3ff3b166e2b80600003d	Zeb1;ZEB1;ZEB	0.9712180347567375
52e92c6e98d0239505000024	RFX6;rfx6	0.8833349278157956
532c0d7fd6d3ac6a3400001c	Genetic Algorithm Similarity Program (GASP)	0.15107727509570856
517194ef8ed59a060a000011	Two enzymes	0.341422274181612
52bf1dea03868f1b06000012	NAUSEA;nausea	0.7029285552808338
532c0d7fd6d3ac6a3400001c	effective alignment of data set	0.08180248084065893
5156be75d24251bc05000088	longitudinal study;Longitudinal Study	0.2662189869936253
52bf1dea03868f1b06000012	INSOMNIA;insomnia	0.5844228588430594
5324cca79b2d7acc7e00001d	weight-loss;Loss, Weight;Weight-loss	0.1597476653055064
5319abffb166e2b80600002f	C1.1 cells	0.3742397420313988
52bf1dea03868f1b06000012	tiredness;fatigue;FATIGUE;TIREDNESS	0.5332123783747745
52bf1dea03868f1b06000012	VOMITING;vomiting	0.5848640881673577
5324cca79b2d7acc7e00001d	a helpful tool	0.1024860798300363
530cefaaad0bf1360c00000d	final;Final	0.09571438794596408
5149a61ed24251bc05000044	beta-barrel finder	0.09268433004294707
5324cca79b2d7acc7e00001d	Physical Activity;physical activity	0.0805334940250213
517194ef8ed59a060a000011	the bird malaria agent P. gallinaceum	0.062091544166494206
52ea605098d0239505000028	alpha-tropomyosin;alpha-Tropomyosin	0.7946932323821229
517194ef8ed59a060a000011	man;Man	0.11603980537742296
530cefaaad0bf1360c00000d	Thyrotropin level;thyrotrophin level;thyrotropin levels;TSH) levels;TSH level	0.5457019511056642
532c0d7fd6d3ac6a3400001c	3D QSAR Pharmacophore Generation module	0.12504401126294956
534ab91eaeec6fbd07000012	RASSF1A	0.8340582304845304
5324cca79b2d7acc7e00001d	dermatology;Dermatology	0.7007809297669922
52ea605098d0239505000028	TPM1	0.7996605512644022
514a11add24251bc05000054	of women with early breast cancer;of all breast cancers;breast cancers in need of;breast cancer;Cancer of Breast;-- Breast Cancer	0.9972890279747862
51600ab3298dcd4e51000036	their profound roles in a wide spectrum	0.06947564510914342
534ab91eaeec6fbd07000012	p14	0.6533722113773686
5156be75d24251bc05000088	SK	0.6866071051913366
534ab91eaeec6fbd07000012	p14(ARF))	0.5968204627029458
534ab91eaeec6fbd07000012	p16	0.9106829691710729
532c0d7fd6d3ac6a3400001c	CatalystHipHop approach	0.2332713644196356
5319abffb166e2b80600002f	the cytomix	0.1238914187417257
532c0d7fd6d3ac6a3400001c	1Ã¢15;1Ã¢15)	0.6626481558711954
531b3ff3b166e2b80600003d	complex;Complex	0.08898496326626294
51656c94298dcd4e51000058	childhood;Childhood	0.10601299318301485
52ea605098d0239505000028	MYH7	0.9289024453411919
531b3ff3b166e2b80600003d	the proper functions of Par protein complex	0.07556942837084639
5156be75d24251bc05000088	(10- to 20-fold) after ocular infection	0.15726753649758918
517194ef8ed59a060a000011	cyanobacteria;Cyanobacteria	0.5891464784986173
5319abffb166e2b80600002f	TGF-beta receptor binding	0.7725252082162223
52ea605098d0239505000028	troponin T;Troponin T	0.6837983087381918
5139b31dbee46bd34c000004	MS patients	0.018221866701512036
516281e6298dcd4e51000040	Anti-Antibodies;antiphosphotyrosine antibodies;anti-phosphotyrosine antibodies	0.8127861394558268
5165932e298dcd4e51000059	5-Aza-2'-deoxycytidine;5-azadeoxycytidine;5 Azadeoxycytidine;5-aza-2'-deoxycytidine;5 aza 2 deoxycytidine	0.9496336527582576
51600ab3298dcd4e51000036	the extent of such up-regulation	0.03988710369448825
5165932e298dcd4e51000059	5 Azacytidine;5-azacytidine;azacytidine;AZACITIDINE;5-Aza;5-aza	0.999612107870501
531b3ff3b166e2b80600003d	SNAIL2;Snail2	0.7948271916321399
5156be75d24251bc05000088	The anti-angiogenic effect of antagomir-132	0.1594351625760777
5319abffb166e2b80600002f	IGF-I;IGF I	0.7542422719880588
5156be75d24251bc05000088	Angiogenesis;angiogenesis	0.6791150725491365
534abe8aaeec6fbd07000013	Hsp70;HSP70;HSP 70	0.9297085544029035
51600ab3298dcd4e51000036	FIBROSIS;fibrosis	0.6539123569557567
5156be75d24251bc05000088	the hallmarks of ALD;ALCOHOLIC LIVER DISEASE;alcoholic diseases of the liver;Alcoholic Liver Disease;ALD	0.8946714846595109
5165932e298dcd4e51000059	5-aza-CdR;5-Aza-CdR	0.8510890953634077
534abe8aaeec6fbd07000013	the induction	0.22858308403595295
513ce3c8bee46bd34c000008	GNAS	0.8052424165247084
5165932e298dcd4e51000059	a nucleoside analog	0.48208685424443054
531b3ff3b166e2b80600003d	EGF	0.7506584365745319
52ece29f98d023950500002c	thyroid hormone transporter	0.026611864333257046
513ce3c8bee46bd34c000008	bp;BP	0.5883467617554474
52ece29f98d023950500002c	MCT8	0.9845454378319332
530cefaaad0bf1360c00000d	Endocrinological;Endocrinology	0.590793093428829
5165932e298dcd4e51000059	5-azacytosine	0.9617796871754337
5324cca79b2d7acc7e00001d	fitness;Fitness	0.08051303434168611
5319abffb166e2b80600002f	epithelial-mesenchymal transition (EMT);epithelial mesenchymal transition (EMT	0.39833520051962673
51600ab3298dcd4e51000036	 cleavag;cleavage	0.6076480716998541
5156be75d24251bc05000088	neuroinflammation	0.6712784445850366
532dcfc9d6d3ac6a34000021	domains of SET;SET Domain;SET domain	0.9999901586295895
5319abffb166e2b80600002f	IGF II;IGF-II	0.9944068616216334
51600ab3298dcd4e51000036	the transmembrane aspartyl protease	0.2780640035840608
52bf1dea03868f1b06000012	all dose levels	0.1771018533527518
52bf1dea03868f1b06000012	as;AS	0.08752348443007232
513ce3c8bee46bd34c000008	MSX2;MSX2 gene	0.9894345704558895
530cefaaad0bf1360c00000d	Mutations;mutations	0.5882286973308188
533ea8fcc45e133714000010	SECIS	0.8846672790677217
514a11add24251bc05000054	Good prognosis;good prognosis	0.20086336680074995
5156be75d24251bc05000088	-- Schizophrenia;schizophrenia	0.8058251407264343
531b3ff3b166e2b80600003d	snail;Snail	0.6726254329075289
5324cca79b2d7acc7e00001d	urine flow	0.3579500509780908
52bf1dea03868f1b06000012	These side effects	0.015041643718763318
534bb147aeec6fbd07000014	negative chronotropy;Negative Chronotropy	0.29342743934516086
517194ef8ed59a060a000011	deltametrin	0.6546298586541254
5165932e298dcd4e51000059	procainamide;PROCAINAMIDE	0.8607967138690523
534bb147aeec6fbd07000014	negative inotropy;Negative Inotropy	0.2904115635904117
5149a61ed24251bc05000044	Increment;increment	0.5903390378775685
533ea8fcc45e133714000010	the transcript	0.18718153903999238
5324cca79b2d7acc7e00001d	other devices	0.10916223971904251
5165932e298dcd4e51000059	Human;human	0.08486582826945241
530cefaaad0bf1360c00000d	seven normal children	0.09613994043764285
513ce3c8bee46bd34c000008	runx2;RUNX2;Runx2	0.8835416033363708
5165932e298dcd4e51000059	Dnmt3A/3L	0.6185497869862306
513ce3c8bee46bd34c000008	Nell-1;NELL-1	0.7440200632489015
52bf1f2d03868f1b06000015	Study;study	0.0832695672337431
5319ac36b166e2b806000031	domain;Domain	0.08548810482657707
52bf1f2d03868f1b06000015	L-dopa;LEVODOPA;levodopa;L-DOPA;l-DOPA;L Dopa;L-Dopa	0.9999999935932431
5165932e298dcd4e51000059	zebularine;Zebularine;zebularine)	0.9809485718360047
5165932e298dcd4e51000059	Vidaza;(Vidaza)	0.8144433368329679
5319ac36b166e2b806000031	Rac1;RAC1	0.817758444805985
5165932e298dcd4e51000059	Dacogen	0.7793761187924196
513ce3c8bee46bd34c000008	SOX6 Gene;SOX6 gene;SOX6	0.6321452543209187
5162e44f298dcd4e5100004a	transgenesis;Transgenesis	0.6333793095733423
531d7430267d7dd053000008	average;Average	0.0847421944508175
530cefaaad0bf1360c00000d	ophthalmologic;Ophthalmologic	0.5933926630053276
52ecf2dd98d023950500002e	Ala92 type 2 deiodinase allele	0.5648822216790534
517194ef8ed59a060a000011	their infectivity with the causative agent	0.024024512724620785
534bb147aeec6fbd07000014	reduced cardiac output	0.14142294644185624
531d7430267d7dd053000008	treatment with placebos	0.15065640932103133
5156be75d24251bc05000088	post-natal brain development	0.2602161498332978
530cefaaad0bf1360c00000d	Periodic evaluations during adulthoo	0.22113234845773352
5156be75d24251bc05000088	a major 4R-tau tauopathy	0.4546489322781516
51600ab3298dcd4e51000036	Acute Myeloid Leukemia;acute myeloid leukemia	0.793671742612414
5162e44f298dcd4e5100004a	gene transfer with viral vectors	0.15658845662788348
5149a61ed24251bc05000044	beta-barrel score	0.027599859251093414
5165932e298dcd4e51000059	silenced genes	0.24199916111832165
514a11add24251bc05000054	colon cancer	0.24687477874085473
530cefaaad0bf1360c00000d	Identified;identified	0.08344642660145642
5173bdb38ed59a060a000020	7	0.8054846965760002
5156be75d24251bc05000088	evidence that miR-132	0.05934749604482452
532dcfc9d6d3ac6a34000021	yeast	0.6375993765990187
5173bdb38ed59a060a000020	seven;Seven	0.09346431987437531
52ee9f55c8da898910000009	Autosomal dominant;autosomal-dominant;autosomal dominant pattern of inheritance;autosomal dominant inheritance;Autosomal Dominant Inheritance;autosomal-dominant inheritance;autosomal dominant	0.997878540053151
5324ce779b2d7acc7e00001e	PREGABALIN;pregabalin;Pregabalin	0.764622938652308
5149a61ed24251bc05000044	one side	0.13322076321401793
530cefaaad0bf1360c000011	dysmnesia;Dysmnesia;memory loss;loss of memory;LOSS OF MEMORY;MEMORY LOSS	0.4284725188428505
513ce3c8bee46bd34c000008	twist;TWIST	0.26583418482887416
51601071298dcd4e51000038	serogroup B Neisseria meningitidis;Meningococcus, Serogroup B;serogroup B meningococcus;Neisseria meningitidis, Serogroup B;Neisseria meningitidis serogroup B	0.9980075662745974
533ea8fcc45e133714000010	selenoprotein genes	0.15818353701930335
531d7430267d7dd053000008	Catuama	0.7115541553345216
531d7430267d7dd053000008	symptoms	0.1422245952429139
532dcfc9d6d3ac6a34000021	methyl group;Methyl Group	0.363465067184409
